<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-144254" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Biomarker Assays for Elevated Prostate-Specific Antigen Risk Analysis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Abdulla</surname>
            <given-names>Adil</given-names>
          </name>
          <aff>Kerala University of Health Sciences</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Leslie</surname>
            <given-names>Stephen W.</given-names>
          </name>
          <aff>Creighton University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Adil Abdulla declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Stephen Leslie declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>7</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-144254.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Serum prostate-specific antigen testing is the primary method for screening and early detection of prostate cancer. This testing is known for its sensitivity but is limited by low specificity. Elevated&#x000a0;levels of prostate-specific antigen can result from benign conditions, leading to potential overdiagnosis and unnecessary biopsies, which strain healthcare resources.&#x000a0;Risk stratification biomarkers are designed for lower-risk and borderline patients, typically with prostate-specific antigen levels between 4 and 10 ng/mL. If test results are negative, these biomarkers help avoid further invasive diagnostics, thus reducing unnecessary procedures. However, for high-risk patients, biopsies remain necessary regardless of biomarker results.</p>
        <p>Current and investigational biomarkers, including blood- and urine-based assays, improve diagnostic accuracy by supplementing prostate-specific antigen testing.&#x000a0;Each biomarker offers unique advantages in detecting, diagnosing, and monitoring prostate cancer, often integrated into risk assessment tools for better clinical decision-making.&#x000a0;Ideal biomarkers are highly sensitive and specific, easy to use, cost-effective, and approved by relevant health authorities, enhancing their use in clinical practice. This activity for healthcare professionals is designed to enhance the learner's understanding of the available risk-stratification biomarkers and those currently investigating to ensure&#x000a0;early and accurate detection of&#x000a0;prostate cancer and improve patient outcomes.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the challenges of adopting serum prostate-specific antigen as the only biomarker for&#x000a0;diagnosing prostate cancer in low-risk and borderline prostate-specific antigen patients.</p></list-item><list-item><p>Interpret various biomarker assays for elevated prostate-specific antigen risk analysis.</p></list-item><list-item><p>Compare the available&#x000a0;biomarker assays for elevated prostate-specific antigen risk analysis.</p></list-item><list-item><p>Implement&#x000a0;interprofessional team strategies to improve care coordination and patient outcomes using&#x000a0;biomarker assays for elevated prostate-specific antigen risk analysis.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=144254&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=144254">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-144254.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Prostate cancer is one of the most frequently detected cancers in males, comprising approximately 1.4 million cases worldwide annually.<xref ref-type="bibr" rid="article-144254.r1">[1]</xref>&#x000a0;Moreover, it is the most commonly diagnosed malignancy and the second leading cause of cancer-related deaths in men, with an estimated 299,000 cases in 2024, according to the National Cancer Institute (NCI).<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/Keywords/UserViewPopup/144254#link_32310541">[2]</ext-link>&#x000a0;Approximately 1 in 8 men develop prostate cancer during their lifetime. However, due to the typically slow progression of the disease, the mortality rate is only 1 in 41 diagnosed men.</p>
        <p>One of the most effective methods for screening, diagnosing, staging, assessing therapeutic response, and predicting prostate cancer is to use various biomarkers in the serum or urine.&#x000a0;According to the NCI, a biomarker is a biological molecule detected in blood, urine, other body fluids, or tissues that can indicate an unhealthy process, condition, or disease.&#x000a0;When properly used, biomarkers enable healthcare professionals to tailor various diagnostic modalities to patients while avoiding unnecessary diagnostic procedures and overtreatment.</p>
        <p>The Early Detection Research Network is the NCI's initiative to identify, develop, and validate future biomarkers and newer technologies for earlier and more accurate cancer diagnosis. These biomarkers could be proteins, DNA, messenger RNA (mRNA), metabolites, prostate cancer cells or derivatives, exosomes, or measurements of various cell cycle processes&#x000a0;such as cellular proliferation or apoptosis.&#x000a0;Several commercial risk-stratification biomarkers for patients with persistently elevated levels of prostate-specific antigen (PSA) and suspected prostate cancer are now available.</p>
        <p>In addition to helping with clinical decision-making in low- or intermediate-risk patients with equivocal PSA levels, surrogate biomarkers can potentially evaluate a particular patient's response to a new drug, procedure, or therapy and determine its utility for that individual. In this way, a biomarker can track the effectiveness of a treatment for a specific disease or condition. Such validated surrogate risk-stratification biomarkers often prevent patients from undergoing lengthy clinical trials, unnecessary biopsies, expensive imaging tests, or other invasive tissue diagnostics.<xref ref-type="bibr" rid="article-144254.r2">[2]</xref></p>
        <p>An ideal biomarker should possess several key attributes&#x02014;highly sensitive and specific, easy to use and interpret, cost-effective, readily available, reproducible, and quantifiable from an easily extractable specimen. In addition, it should have a high negative predictive value of at least 90%, approved by the Food and Drug Administration (FDA) and Clinical Laboratory Improvement Amendments (CLIA), and recommended by the National Comprehensive Cancer Network (NCCN).</p>
        <p>Prostatic risk-stratification biomarkers are intended for use primarily in lower-risk and selected borderline patients with marginally elevated levels of PSA, typically between 4&#x000a0;and 10 ng/mL, where an adverse finding likely results in the avoidance of immediate further testing, prostatic imaging, biopsies, or other diagnostic procedures.<xref ref-type="bibr" rid="article-144254.r1">[1]</xref><xref ref-type="bibr" rid="article-144254.r2">[2]</xref>&#x000a0;This&#x000a0;activity reviews the current status of the available risk-stratification biomarkers and those undergoing investigation.</p>
      </sec>
      <sec id="article-144254.s3" sec-type="Etiology and Epidemiology">
        <title>Etiology and Epidemiology</title>
        <p>The International Agency for Research on Cancer estimates that 1,414,259 new cases of prostate cancer are diagnosed worldwide yearly, resulting in 375,304 deaths. In the United States, the SEER (Surveillance, Epidemiology, and End Results) database estimates about 299,000 new cases and 35,250 deaths due to prostate cancer in 2024. Prostate cancer accounts for 15% of all new cancer diagnoses and 5.7% of cancer-related deaths annually. However, 5-year relative survival is estimated to be 98.6%.</p>
        <p>The incidence of prostate malignancy has a geographical variation, with the highest in Australia/New Zealand, North America, and parts of Europe, primarily due to the employment of PSA testing and an aging population. Even though prostate cancer mortality has relatively less variation worldwide, the rates are exceptionally high among the Black population in the Caribbean and sub-Saharan Africa, intermediate in the United States, and lowest in South Central Asia.</p>
        <p>Sixty-six percent of prostate cancer cases are diagnosed in individuals older than 65, with the average age of initial diagnosis being 66. Although the exact etiology is unknown, genetic predisposition and family history are clearly associated with an increased risk of prostate cancer.<xref ref-type="bibr" rid="article-144254.r1">[1]</xref><xref ref-type="bibr" rid="article-144254.r3">[3]</xref>&#x000a0;A small subset of patients with prostate cancer have a hereditary form of the disease. On average, these patients are diagnosed 6 to 7&#x000a0;years earlier than the general population. However, the clinical course and aggressiveness of cancers do not seem to differ.<xref ref-type="bibr" rid="article-144254.r4">[4]</xref></p>
        <p>Genomic evaluation has identified more than 100 genes contributing to the risk of prostatic malignancy.<xref ref-type="bibr" rid="article-144254.r5">[5]</xref><xref ref-type="bibr" rid="article-144254.r6">[6]</xref><xref ref-type="bibr" rid="article-144254.r7">[7]</xref>&#x000a0;About 15% to 17% of the prostate cancer population have been identified as having germline mutations. Such mutations are independent of the cancer stage. A study of multigene testing among men with prostate cancer across the United States by Giri et al concluded that 15.6% of the study population had pathogenic variations of the genes studied, including <italic toggle="yes">BRCA1</italic>,<italic toggle="yes"> BRCA2</italic>,<italic toggle="yes"> HOXB13</italic>,<italic toggle="yes"> MLH1</italic>,<italic toggle="yes"> MSH2</italic>,<italic toggle="yes"> PMS2</italic>,<italic toggle="yes"> MSH6</italic>,<italic toggle="yes"> EPCAM</italic>,<italic toggle="yes"> ATM CHEK2</italic>,<italic toggle="yes"> NBN</italic>, and&#x000a0;<italic toggle="yes">TP53</italic>.<xref ref-type="bibr" rid="article-144254.r8">[8]</xref><xref ref-type="bibr" rid="article-144254.r9">[9]</xref>&#x000a0;The most commonly found pathologic gene variation identified was <italic toggle="yes">BRCA2</italic> (4.5%).<xref ref-type="bibr" rid="article-144254.r8">[8]</xref>&#x000a0;Nicolosi et al reported that 17.2% of the study population had a pathogenic germline variant, and genomic analysis could help identify high-risk families.<xref ref-type="bibr" rid="article-144254.r10">[10]</xref><xref ref-type="bibr" rid="article-144254.r11">[11]</xref><xref ref-type="bibr" rid="article-144254.r12">[12]</xref></p>
        <p>The Identification of Men with a Genetic Predisposition to Prostate Cancer (IMPACT) study evaluated men aged 40 to 69 with <italic toggle="yes">BRCA1</italic> or <italic toggle="yes">BRCA2</italic> germline mutations by screening with PSA annually and targeted biopsy if PSA &#x0003e;3.0 ng/mL.<xref ref-type="bibr" rid="article-144254.r13">[13]</xref> After about 3 years of research, it was found that <italic toggle="yes">BRCA2</italic> mutation carriers were more likely to develop prostate cancer, have a younger age of onset, and develop more clinically apparent tumors compared to noncarriers.<xref ref-type="bibr" rid="article-144254.r13">[13]</xref></p>
        <p>Many exogenous factors are associated with the likelihood of developing prostate cancer, including metabolic syndrome, diabetes, obesity, dyslipidemia, Agent Orange exposure, and various dietary factors.<xref ref-type="bibr" rid="article-144254.r2">[2]</xref> Japanese men have less risk of prostate cancer compared to Western men, but the risk increases substantially if they migrate to the United States, implying an interplay of environmental, dietary, or lifestyle factors.<xref ref-type="bibr" rid="article-144254.r14">[14]</xref>&#x000a0;However, no proven dietary, lifestyle, or pharmacological therapy for the prevention of prostate cancer has been established.</p>
      </sec>
      <sec id="article-144254.s4" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Inflammation of the prostate gland, often caused by various genetic mutations, is the earliest sign of prostate cancer. This inflammation leads to oxidative damage, which causes telomeres at the ends of chromosomes to shorten, eventually initiating the development of prostate cancer. Several genes, including <italic toggle="yes">MYC</italic>,<italic toggle="yes"> PTEN</italic>,<italic toggle="yes"> NKX3.1</italic>, and the <italic toggle="yes">TMPRSS2-ERG</italic> gene fusion, have been identified in the initiation and development of prostate cancer, even though no single tumor suppressor gene is primarily responsible.</p>
        <p>The TMPRSS2-ERG gene fusion activates the ERG oncogenic pathway, which is linked to the emergence of illness.&#x000a0;The reactivation of cell cycle pathways causes unchecked cell proliferation, promoting the tumor's metastatic spread.&#x000a0;Gene expression profiling of metastatic illness identifies overexpression in EZH2 mRNA and proteins. Due to its role in apoptosis and proliferation, EZH2 is currently under research as a new prostate cancer target.</p>
      </sec>
      <sec id="article-144254.s5" sec-type="Specimen Requirements and Procedure">
        <title>Specimen Requirements and Procedure</title>
        <p>Current and investigational biomarkers, including blood-based and urine-based assays, improve diagnostic accuracy by supplementing PSA testing. These biomarkers include derivatives of PSA, such as PSA density and velocity, and newer molecular forms, such as (-2) pro-PSA. Other significant biomarkers include the Prostate health index (PHI), the 4K score, prostate cancer antigen 3 (PCA3), and <italic toggle="yes">TMPRSS2-ERG</italic> gene fusions (see&#x000a0;<bold>Table.</bold>&#x000a0;Biomarkers Used for Prostate-Specific Antigen Testing).</p>
        <p>Each biomarker offers unique advantages in detecting, diagnosing, and monitoring prostate cancer and is often integrated into risk assessment tools for better clinical decision-making. Their high negative predictive values allow clinicians to confidently rule out the need for further testing in many cases, thus preventing overdiagnosis and reducing the burden on patients and healthcare systems.</p>
        <table-wrap id="article-144254.table0" position="float" orientation="portrait">
          <caption>
            <title>Table. Biomarkers Used for Prostate-Specific Antigen Testing</title>
          </caption>
          <table style="border-color: black; width: 1100px; float: left;" border="1" cellspacing="1" cellpadding="2">
            <tbody>
              <tr style="height: 59px; text-align: center;">
                <td style="width: 229px; height: 59px; text-align: center;" rowspan="1" colspan="1">
<p><bold>Biomarkers Tested</bold></p>
</td>
                <td style="width: 210px; height: 59px;" rowspan="1" colspan="1">
<p><bold>Commercial&#x000a0;</bold><bold>Available Tests</bold></p>
</td>
                <td style="width: 97px; height: 59px; text-align: center;" rowspan="1" colspan="1">
<p><bold>Specimen&#x000a0;</bold></p>
</td>
                <td style="width: 37.2639px; height: 59px; text-align: center;" rowspan="1" colspan="1">
<p><bold>Cutoff</bold></p>
</td>
                <td style="width: 239.736px; height: 59px; text-align: center;" rowspan="1" colspan="1">
<bold>Sensitivity</bold>
</td>
                <td style="width: 208px; height: 59px; text-align: center;" rowspan="1" colspan="1">
<p><bold>Specificity</bold></p>
</td>
                <td style="width: 494px; height: 59px; text-align: center;" rowspan="1" colspan="1">
<bold>Negative Predictive Value</bold>
</td>
                <td style="width: 96px; height: 59px; text-align: center;" rowspan="1" colspan="1">
<p><bold>Approval/ Certification</bold><bold>&#x000a0;</bold></p>
</td>
                <td style="width: 100px; height: 59px; text-align: center;" rowspan="1" colspan="1">
<p><bold>Recommendations&#x000a0;</bold><bold>by NCCN</bold></p>
</td>
                <td style="width: 416px; height: 59px; text-align: center;" rowspan="1" colspan="1">
<p><bold>At-Home Collection Kit</bold></p>
</td>
              </tr>
              <tr style="height: 26.0903px; text-align: center;">
                <td style="width: 229px; height: 26.0903px; text-align: left;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Total PSA</p></list-item><list-item><p>Free PSA</p></list-item><list-item><p>(-2) pro-PSA</p></list-item></list>
</td>
                <td style="width: 210px; height: 26.0903px;" rowspan="1" colspan="1">
<p>&#x000a0;Prostate health index</p>
<p>(PHI)</p>
</td>
                <td style="width: 97px; height: 26.0903px; text-align: center;" rowspan="1" colspan="1">
<p>Serum</p>
</td>
                <td style="width: 37.2639px; height: 26.0903px; text-align: center;" rowspan="1" colspan="1">
<p>&#x000a0;27</p>
</td>
                <td style="width: 239.736px; height: 26.0903px; text-align: center;" rowspan="1" colspan="1">90%</td>
                <td style="width: 208px; height: 26.0903px; text-align: center;" rowspan="1" colspan="1">
<p>31.1%@ Sensitivity 90%&#x000a0;<xref ref-type="bibr" rid="article-144254.r15">[15]</xref></p>
</td>
                <td style="width: 494px; height: 26.0903px; text-align: center;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>89% for any prostate cancer</p></list-item><list-item><p>97% for clinically significant prostate cancer&#x000a0;<xref ref-type="bibr" rid="article-144254.r16">[16]</xref>&#x000a0;</p></list-item></list>
</td>
                <td style="width: 96px; height: 26.0903px; text-align: center;" rowspan="1" colspan="1">
<p>FDA</p>
</td>
                <td style="width: 100px; height: 26.0903px; text-align: center;" rowspan="1" colspan="1">
<p>IB and RB</p>
</td>
                <td style="width: 416px; height: 26.0903px; text-align: center;" rowspan="1" colspan="1">
<p>NA</p>
</td>
              </tr>
              <tr style="height: 16px; text-align: center;">
                <td style="width: 229px; height: 16px; text-align: left;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Total PSA</p></list-item><list-item><p>Free PSA</p></list-item><list-item><p>Intact PSA</p></list-item><list-item><p>hK2</p></list-item></list>
</td>
                <td style="width: 210px; height: 16px;" rowspan="1" colspan="1">&#x000a0;4K Score</td>
                <td style="width: 97px; height: 16px;" rowspan="1" colspan="1">
<p>Serum</p>
</td>
                <td style="width: 37.2639px; height: 16px;" rowspan="1" colspan="1">
<p>7.5%</p>
</td>
                <td style="width: 239.736px; height: 16px;" rowspan="1" colspan="1">
<p>89%&#x000a0;</p>
</td>
                <td style="width: 208px; height: 16px;" rowspan="1" colspan="1">
<p>29%</p>
</td>
                <td style="width: 494px; height: 16px;" rowspan="1" colspan="1">
<p>&#x000a0;95%&#x000a0;<xref ref-type="bibr" rid="article-144254.r17">[17]</xref></p>
</td>
                <td style="width: 96px; height: 16px;" rowspan="1" colspan="1">
<p>&#x000a0;FDA</p>
</td>
                <td style="width: 100px; height: 16px;" rowspan="1" colspan="1">&#x000a0;
<p>IB and RB</p>
</td>
                <td style="width: 416px; height: 16px;" rowspan="1" colspan="1">NA</td>
              </tr>
              <tr style="height: 35px; text-align: center;">
                <td style="width: 229px; height: 35px; text-align: left;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>PCA3</p></list-item></list>
</td>
                <td style="width: 210px; height: 35px;" rowspan="1" colspan="1">&#x000a0;PCA3</td>
                <td style="width: 97px; height: 35px;" rowspan="1" colspan="1">
<p>Urine</p>
</td>
                <td style="width: 37.2639px; height: 35px;" rowspan="1" colspan="1">
<p>25</p>
</td>
                <td style="width: 239.736px; height: 35px;" rowspan="1" colspan="1">
<p>&#x000a0;78%</p>
</td>
                <td style="width: 208px; height: 35px;" rowspan="1" colspan="1">
<p>57%</p>
</td>
                <td style="width: 494px; height: 35px;" rowspan="1" colspan="1">
<p>90%&#x000a0;<xref ref-type="bibr" rid="article-144254.r18">[18]</xref></p>
</td>
                <td style="width: 96px; height: 35px;" rowspan="1" colspan="1">
<p>&#x000a0;FDA</p>
</td>
                <td style="width: 100px; height: 35px;" rowspan="1" colspan="1">RB only</td>
                <td style="width: 416px; height: 35px;" rowspan="1" colspan="1">NA</td>
              </tr>
              <tr style="height: 35px; text-align: center;">
                <td style="width: 229px; height: 35px; text-align: left;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Exosomal RNA (PCA3, RNA)</p></list-item></list>
</td>
                <td style="width: 210px; height: 35px;" rowspan="1" colspan="1">
<p>ExoDx Prostate Intelliscore</p>
</td>
                <td style="width: 97px; height: 35px;" rowspan="1" colspan="1">
<p>Urine</p>
</td>
                <td style="width: 37.2639px; height: 35px;" rowspan="1" colspan="1">
<p>15.6</p>
</td>
                <td style="width: 239.736px; height: 35px; text-align: left;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>IB 92%</p></list-item><list-item><p>RB 82%</p></list-item></list>
</td>
                <td style="width: 208px; height: 35px; text-align: center;" rowspan="1" colspan="1">NA&#x000a0;</td>
                <td style="width: 494px; height: 35px; text-align: left;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>IB 91%</p></list-item><list-item><p>RB 92%&#x000a0;<xref ref-type="bibr" rid="article-144254.r19">[19]</xref></p></list-item></list>
</td>
                <td style="width: 96px; height: 35px;" rowspan="1" colspan="1">
<p>&#x000a0;FDA</p>
</td>
                <td style="width: 100px; height: 35px;" rowspan="1" colspan="1">&#x000a0;
<p>IB and RB</p>
</td>
                <td style="width: 416px; height: 35px;" rowspan="1" colspan="1">Available</td>
              </tr>
              <tr style="height: 35px; text-align: center;">
                <td style="width: 229px; height: 35px; text-align: left;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>PCA3</p></list-item><list-item><p><italic toggle="yes">TMPRSS2-ERG</italic> gene fusion</p></list-item><list-item><p>Serum PSA</p></list-item></list>
</td>
                <td style="width: 210px; height: 35px;" rowspan="1" colspan="1">&#x000a0;My Prostate Score 2.0</td>
                <td style="width: 97px; height: 35px;" rowspan="1" colspan="1">
<p>Urine, Serum</p>
</td>
                <td style="width: 37.2639px; height: 35px;" rowspan="1" colspan="1">No recommended cutoff&#x000a0;</td>
                <td style="width: 239.736px; height: 35px;" rowspan="1" colspan="1">93%</td>
                <td style="width: 208px; height: 35px;" rowspan="1" colspan="1">&#x000a0;33%&#x000a0;<xref ref-type="bibr" rid="article-144254.r20">[20]</xref></td>
                <td style="width: 494px; height: 35px;" rowspan="1" colspan="1">90% for any prostate cancer&#x000a0;<xref ref-type="bibr" rid="article-144254.r21">[21]</xref></td>
                <td style="width: 96px; height: 35px;" rowspan="1" colspan="1">
<p>CLIA</p>
</td>
                <td style="width: 100px; height: 35px;" rowspan="1" colspan="1">&#x000a0;Investigational</td>
                <td style="width: 416px; height: 35px;" rowspan="1" colspan="1">NA</td>
              </tr>
              <tr style="height: 35px; text-align: center;">
                <td style="width: 229px; height: 35px; text-align: left;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>HOXC6</p></list-item><list-item><p>DLX1</p></list-item><list-item><p>Serum PSA</p></list-item></list>
</td>
                <td style="width: 210px; height: 35px;" rowspan="1" colspan="1">&#x000a0;Select MDx</td>
                <td style="width: 97px; height: 35px;" rowspan="1" colspan="1">
<p>Urine, Serum</p>
</td>
                <td style="width: 37.2639px; height: 35px;" rowspan="1" colspan="1">
<p>&#x000a0;PSA &#x0003c;10</p>
</td>
                <td style="width: 239.736px; height: 35px;" rowspan="1" colspan="1">
<p>&#x000a0;89%</p>
</td>
                <td style="width: 208px; height: 35px;" rowspan="1" colspan="1">
<p>&#x000a0;53%</p>
</td>
                <td style="width: 494px; height: 35px;" rowspan="1" colspan="1">
<p>&#x000a0;95%&#x000a0;<xref ref-type="bibr" rid="article-144254.r22">[22]</xref></p>
</td>
                <td style="width: 96px; height: 35px;" rowspan="1" colspan="1">
<p>CLIA</p>
</td>
                <td style="width: 100px; height: 35px;" rowspan="1" colspan="1">
<p>IB and RB</p>
</td>
                <td style="width: 416px; height: 35px;" rowspan="1" colspan="1">
<p>NA</p>
</td>
              </tr>
              <tr style="height: 102px;">
                <td style="width: 229px; height: 102px; text-align: left;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Sarcosine</p></list-item><list-item><p>Alanine</p></list-item><list-item><p>Glycine</p></list-item><list-item><p>Glutamate&#x000a0;</p></list-item></list>
</td>
                <td style="width: 210px; height: 102px; text-align: center;" rowspan="1" colspan="1">Prostarix risk score</td>
                <td style="width: 97px; height: 102px; text-align: center;" rowspan="1" colspan="1">
<p>Urine</p>
</td>
                <td style="width: 37.2639px; height: 102px; text-align: center;" rowspan="1" colspan="1">NA</td>
                <td style="width: 239.736px; height: 102px; text-align: center;" rowspan="1" colspan="1">&#x000a0;NA</td>
                <td style="width: 208px; height: 102px; text-align: center;" rowspan="1" colspan="1">NA</td>
                <td style="width: 494px; height: 102px; text-align: center;" rowspan="1" colspan="1">NA</td>
                <td style="width: 96px; height: 102px; text-align: center;" rowspan="1" colspan="1">
<p>CLIA</p>
</td>
                <td style="width: 100px; height: 102px; text-align: center;" rowspan="1" colspan="1">&#x000a0;NA</td>
                <td style="width: 416px; height: 102px; text-align: center;" rowspan="1" colspan="1">NA</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>IB, The clinical decision for the initial biopsy; RB, Repeat biopsy in prior negative biopsy; NA, Not available.</p>
        <p>The NCCN has recognized the PHI, 4K Score, ExoDx Intelliscore, My Prostate Score, Select MDx, and ConfirmMDx (a tissue confirmation test).</p>
      </sec>
      <sec id="article-144254.s6" sec-type="Diagnostic Tests">
        <title>Diagnostic Tests</title>
        <p>
<bold>Blood-Based Biomarkers</bold>
</p>
        <p><bold>Prostate-specific antigen:&#x000a0;</bold>PSA, a member of the kallikrein gene family, was first identified and isolated in 1979.<xref ref-type="bibr" rid="article-144254.r23">[23]</xref> PSA is secreted by prostatic ductal and acinar epithelium and is highly organ-specific. PSA is circulated in free (fPSA) and protein-bound forms (complexed). The expression of PSA is androgen-dependent and is a crucial tool for the early detection, staging, treatment planning, and prognosis of prostate cancer. The widespread use of PSA testing in the 1990s led to increased prostate cancer diagnoses and a subsequent decline in mortality rates for this disease.</p>
        <p>Even though PSA is an excellent and sensitive biomarker, the biomarker is organ-specific but not disease-specific. Prostatic basal layer and basement membrane violations allow PSA to escape prostate cells and enter the bloodstream, leading to an increase in serum PSA levels.<xref ref-type="bibr" rid="article-144254.r24">[24]</xref><xref ref-type="bibr" rid="article-144254.r25">[25]</xref>&#x000a0;This&#x000a0;increase in serum PSA levels may occur in several prostatic pathologies, such as benign prostatic hyperplasia, prostatitis, or prostate malignancy, or transiently with prostatic manipulation, as in prostate biopsies, prostatic massage, or urethral catheterization.<xref ref-type="bibr" rid="article-144254.r23">[23]</xref><xref ref-type="bibr" rid="article-144254.r26">[26]</xref><xref ref-type="bibr" rid="article-144254.r27">[27]</xref><xref ref-type="bibr" rid="article-144254.r28">[28]</xref><xref ref-type="bibr" rid="article-144254.r29">[29]</xref></p>
        <p>Treatment with 5-alpha-reductase inhibitors has been shown to reduce PSA levels by approximately 50% when treated for &#x02265;6 months.<xref ref-type="bibr" rid="article-144254.r30">[30]</xref><xref ref-type="bibr" rid="article-144254.r31">[31]</xref> Despite this, multiple guidelines still recommend PSA as the primary tool for initial prostate cancer screening. However, experts have yet to agree on the subset of patients to screen, the appropriate age to start screening, and other relevant factors to consider. All guidelines recommend that prostate cancer screening be an informed decision made after shared decision-making and a risk-benefit analysis. The most scientifically correct and reasonable guideline is from the American Urological Association (AUA), as it takes into account high-risk factors, the known incidence of prostate cancer appearing in some individuals before 50, and the longer life expectancy of men, which now averages 87 years.<xref ref-type="bibr" rid="article-144254.r2">[2]</xref></p>
        <p>The following recommendations have been established by the AUA and the Society for Urologic Oncology (SUO):</p>
        <list list-type="bullet">
          <list-item>
            <p>PSA screening in men younger than 40 is not recommended.</p>
          </list-item>
          <list-item>
            <p>Screening may be offered to men at high risk starting at age 40, such as those of Black ethnicity, those with a family history of prostate cancer, and&#x000a0;those with&#x000a0;<italic toggle="yes">BRCA1</italic> and <italic toggle="yes">BRCA2</italic> germline mutations.</p>
          </list-item>
          <list-item>
            <p>Routine screening for men at average risk may be offered starting at age 45.</p>
          </list-item>
          <list-item>
            <p>Two separate high PSA levels are necessary before further investigations are performed.</p>
          </list-item>
          <list-item>
            <p>Shared decision-making is recommended for men where PSA screening is being considered, proceeding based on the individual's values and preferences.</p>
          </list-item>
          <list-item>
            <p>Regular screening may be offered every 2 to 4 years but can be personalized based on patient preferences, age, PSA, prostate cancer risk, comorbidities, life expectancy, and general health considerations.</p>
          </list-item>
          <list-item>
            <p>Men with a reasonable life expectancy of &#x02264;10 years should not be offered routine screening as they are unlikely to benefit from it.</p>
          </list-item>
          <list-item>
            <p>Routine PSA screening in men aged 70 and older should be based on shared decision-making and individual patient preferences, life expectancy, and general health.</p>
          </list-item>
          <list-item>
            <p>Screenings may be discontinued or the interval substantially lengthened for patients aged 75 or older if the PSA is &#x0003c;3 ng/mL.<xref ref-type="bibr" rid="article-144254.r2">[2]</xref><xref ref-type="bibr" rid="article-144254.r32">[32]</xref><xref ref-type="bibr" rid="article-144254.r33">[33]</xref></p>
          </list-item>
        </list>
        <p>A baseline PSA level that predicts the likelihood of prostate malignancy detection and the chance of developing high-grade prostate malignancy can customize the rescreening intervals. According to several studies, screening intervals of 2 to 4 years are unlikely to miss curable prostate cancer.<xref ref-type="bibr" rid="article-144254.r32">[32]</xref><xref ref-type="bibr" rid="article-144254.r34">[34]</xref><xref ref-type="bibr" rid="article-144254.r35">[35]</xref> Therefore, the AUA recommends a 2-year screening as a reasonable approach. The AUA suggests that men older than 60 with PSA levels below 1.0 ng/mL may benefit from prolonged screening intervals, such as 2 to 4 years.<xref ref-type="bibr" rid="article-144254.r32">[32]</xref></p>
        <p><bold>Prostate risk stratification biomarkers: </bold>The primary purpose of prostate risk stratification biomarker tests is to identify patients with a negative result&#x000a0;who do not require further immediate testing, imaging, or biopsies.<xref ref-type="bibr" rid="article-144254.r2">[2]</xref><bold>&#x000a0;</bold>These&#x000a0;biomarkers are primarily intended for use in lower-risk and selected borderline patients, a subset with PIRADS 3 lesion on multiparametric magnetic resonance imaging (MRI), with slightly elevated levels of PSA, typically 4 to 10 ng/mL. In these cases, a negative test result can reasonably halt additional testing, prostate&#x000a0;imaging, biopsies, and other diagnostic procedures, allowing for the resumption of routine screening.<xref ref-type="bibr" rid="article-144254.r1">[1]</xref><xref ref-type="bibr" rid="article-144254.r2">[2]</xref>&#x000a0;Due to their high negative predictive value, these tests help clinicians determine the likelihood of detecting a clinically significant malignancy by further evaluation, which is low, and that further immediate investigation is unnecessary.<xref ref-type="bibr" rid="article-144254.r1">[1]</xref></p>
        <p>However, this approach is not recommended if the PSA is &#x0003e;10 ng/mL or the patient is otherwise in the high-risk category. The high-risk group&#x000a0;includes men of African descent; those with a family history of prostate malignancy; those with germline mutations that increase the risk for prostate cancer, such as&#x000a0;<italic toggle="yes">BRCA1</italic>,<italic toggle="yes"> ATM</italic>,<italic toggle="yes"> CHEK2</italic>, and <italic toggle="yes">BRAC2;</italic>&#x000a0;men with a family history of multiple malignancies or Lynch syndrome; and those with known exposure to Agent Orange.<xref ref-type="bibr" rid="article-144254.r2">[2]</xref><xref ref-type="bibr" rid="article-144254.r36">[36]</xref><xref ref-type="bibr" rid="article-144254.r37">[37]</xref><xref ref-type="bibr" rid="article-144254.r38">[38]</xref><xref ref-type="bibr" rid="article-144254.r39">[39]</xref><xref ref-type="bibr" rid="article-144254.r40">[40]</xref>&#x000a0;These patients should proceed with a biopsy as a clinically significant malignancy is more likely than average. Therefore, clinicians can generally skip prostatic risk stratification biomarkers in high-risk patients with elevated levels of PSA.<xref ref-type="bibr" rid="article-144254.r1">[1]</xref>&#x000a0;</p>
        <p><bold>Prostate-specific antigen derivatives:&#x000a0;</bold>Clinical decision-making is enhanced using PSA derivatives, such as PSA density, velocity, doubling time, age-adjusted values, and, recently, different molecular derivatives. PSA velocity is the rate of change of PSA over a year, whereas PSA density is the PSA-derived computation of total PSA (tPSA) divided by prostatic volume. The PSA doubling time measures how quickly a rising PSA level increases to double its value, gauging the rate-dependent exponential rise in serum PSA over time<bold>. </bold>These PSA-derived metrics are used for decision-making regarding prostate biopsy in an early detection setting.</p>
        <p>Among the derivatives, PSA density shows substantially better predictive information compared to PSA velocity. A higher PSA density has a greater likelihood of clinically significant prostate cancer, particularly in smaller prostates, when a value of 0.15 ng/mL/cc was considered.<xref ref-type="bibr" rid="article-144254.r41">[41]</xref>&#x000a0;</p>
        <p>Research suggests that a PSA density of 0.1&#x000a0;to 0.15 ng/mL/cc or higher is considered significant (higher risk). In contrast, a value lower than 0.09 ng/mL/cc is considered insignificant (&#x0003c;4% chance).<xref ref-type="bibr" rid="article-144254.r42">[42]</xref><xref ref-type="bibr" rid="article-144254.r43">[43]</xref><xref ref-type="bibr" rid="article-144254.r44">[44]</xref>&#x000a0;A PSA density of 0.15 ng/cc is typically the cutoff point.<xref ref-type="bibr" rid="article-144254.r45">[45]</xref><xref ref-type="bibr" rid="article-144254.r46">[46]</xref><xref ref-type="bibr" rid="article-144254.r47">[47]</xref><xref ref-type="bibr" rid="article-144254.r48">[48]</xref> PSA velocity and doubling time have limited diagnostic value but may aid in prognostification.<xref ref-type="bibr" rid="article-144254.r49">[49]</xref></p>
        <p>Studies have shown a correlation between a low percentage of fPSA and aggressive pathological features.<xref ref-type="bibr" rid="article-144254.r50">[50]</xref><xref ref-type="bibr" rid="article-144254.r51">[51]</xref>&#x000a0;The percentage of fPSA production was less in malignant prostates compared to men without.<xref ref-type="bibr" rid="article-144254.r52">[52]</xref><xref ref-type="bibr" rid="article-144254.r53">[53]</xref><xref ref-type="bibr" rid="article-144254.r54">[54]</xref><xref ref-type="bibr" rid="article-144254.r55">[55]</xref>&#x000a0;This observation led to the development of fPSA testing as an adjunct to improve the accuracy of PSA as a prostate cancer biomarker.<xref ref-type="bibr" rid="article-144254.r56">[56]</xref><xref ref-type="bibr" rid="article-144254.r57">[57]</xref>&#x000a0;</p>
        <p>The United States FDA approved using fPSA as a biomarker to enhance screening in males with blood PSA levels of 4 to 10 ng/mL and a negative digital rectal examination. A percentage fPSA cutoff of 18% has improved the detection of prostate cancer in men when compared to tPSA alone. Such patients are recommended for prostate biopsy. The prostate malignancy detection was 56% in men with a percentage of fPSA &#x0003c;10 % compared to 8% when the percentage of fPSA was &#x0003e;25%.<xref ref-type="bibr" rid="article-144254.r57">[57]</xref><xref ref-type="bibr" rid="article-144254.r58">[58]</xref>&#x000a0;</p>
        <p>The NCCN recommends incorporating the percentage of fPSA for decision-making for prostate biopsy and recommends a cutoff of 10%.<xref ref-type="bibr" rid="article-144254.r59">[59]</xref>&#x000a0;However, it has no clinical implication in patients with tPSA &#x0003e;10 ng/mL or in the follow-up of known prostate cancer patients. The use of predictive calculators incorporating multiple clinical variables&#x000a0;such as tPSA, fPSA percentage, and digital rectal examination (DRE) findings for shared decision-making has increased.<xref ref-type="bibr" rid="article-144254.r60">[60]</xref><xref ref-type="bibr" rid="article-144254.r61">[61]</xref><xref ref-type="bibr" rid="article-144254.r62">[62]</xref></p>
        <p><bold>Free prostate<italic toggle="yes">-</italic>specific antigen isoforms:&#x000a0;</bold>The serum isoforms of fPSA, namely pro-PSA, benign PSA, and intact fPSA, exist in equal concentrations in serum and are promising biomarkers. Studies have shown significant levels of truncated forms of PSA in malignant prostate&#x000a0;tissues&#x000a0;such as (-2) pro-PSA. Applying (-2) pro-PSA has been validated as a screening biomarker before a biopsy.<xref ref-type="bibr" rid="article-144254.r15">[15]</xref><xref ref-type="bibr" rid="article-144254.r16">[16]</xref>&#x000a0;</p>
        <p>(-2) pro-PSA is also a strong predictor of histological aggressiveness,&#x000a0;indicated by a Gleason score of &#x02265;7). Studies have shown that (-2) pro-PSA is superior to PSA and fPSA percentage as a biomarker in predicting prostate malignancy in men planned for biopsy with a serum PSA of 4 to 10 ng/mL. In addition, it correlates with the pathological aggressiveness of the tumor.</p>
        <p><bold>Prostate health index:&#x000a0;</bold>PHI is a blood-based biomarker that can predict the risk of aggressive prostate malignancy,&#x000a0;indicated by a Gleason score of &#x02265;7, at biopsy. This assay analyzes tPSA, fPSA, and (-2) pro-PSA levels. PHI was approved in 2012 by the FDA to diagnose prostate cancer in men aged 50 and older with a clinically negative DRE and PSA of 4 to 10 ng/mL.<xref ref-type="bibr" rid="article-144254.r63">[63]</xref><xref ref-type="bibr" rid="article-144254.r64">[64]</xref></p>
        <p>PHI has consistently shown superiority over tPSA and fPSA in the early detection of prostate cancer. As a result, it has been added to various web-based risk assessment calculators, such as the prostate cancer prevention trial (PCPT) calculator.<xref ref-type="bibr" rid="article-144254.r15">[15]</xref><xref ref-type="bibr" rid="article-144254.r65">[65]</xref>&#x000a0;The NCCN recommended using PHI in early cancer detection in 2015. However, due to limited studies in the United States population, it is not recommended as first-line screening for all patients.</p>
        <p><bold>Human kallikrein 2 and 4K score:&#x000a0;</bold>Human kallikrein 2 (hK2) shares many similarities with PSA. They are both regulated by androgens, are proteases, and have an identical specificity for the prostate.<xref ref-type="bibr" rid="article-144254.r66">[66]</xref> However, in contrast to PSA, hK2 is a much more potent protease and is selectively expressed in cancerous tissue, where its expression correlates with the aggressiveness of malignancy, degree of differentiation, and biochemical recurrence.<xref ref-type="bibr" rid="article-144254.r66">[66]</xref> Combining fPSA with hK2 has increased the cancer detection rate in the&#x000a0;4&#x000a0;to 10 ng/mL PSA range.</p>
        <p>In the 4K score assay, the 4 kallikrein proteins&#x02014;tPSA, fPSA, intact PSA, and hK2&#x02014;were integrated. The 4K score has been included in the NCCN prostate cancer early detection guidelines.<xref ref-type="bibr" rid="article-144254.r67">[67]</xref>&#x000a0;The 4K score&#x000a0;predicts the likelihood of biopsy-positive prostate cancer when paired with clinical characteristics, including age and prior negative biopsies. This biomarker also accurately predicts the aggressiveness of cancer.<xref ref-type="bibr" rid="article-144254.r68">[68]</xref>&#x000a0;Meta-analysis has been shown to improve the predictive accuracy of biopsy by 8% to 10% and decrease the rate of unwanted biopsies by 48% to 56%.<xref ref-type="bibr" rid="article-144254.r69">[69]</xref>&#x000a0;The 4K score also predicts the risk of distant metastasis even 20 years later in men with a PSA of &#x02265;2 ng/mL. The NCCN has recommended the 4K score for appropriate patients.</p>
        <p><bold>Serum protein panel:&#x000a0;</bold>The 3 prostate cancer biomarkers&#x02014;FilamenA, FilamenB, and Keratin19&#x02014;have been combined into a novel serum protein panel for disease screening and prognosis due to recent studies. A panel of these biomarkers with PSA outperformed PSA alone in diagnosing, predicting aggressiveness, and differentiating cancer from benign prostatic hyperplasia.<xref ref-type="bibr" rid="article-144254.r70">[70]</xref></p>
        <p>
<bold>Urine-Based Biomarkers</bold>
</p>
        <p><bold>Prostate cancer antigen 3:&#x000a0;</bold>The ease of collecting urine specimens and the knowledge regarding the exfoliation of prostate cells in the urine have made urine a source for potential biomarker research.<xref ref-type="bibr" rid="article-144254.r71">[71]</xref>&#x000a0;The transcriptome comparison of prostate cancer and normal tissues led to the identification of PCA3.<xref ref-type="bibr" rid="article-144254.r72">[72]</xref>&#x000a0;Formerly known as differential display code 3, PCA3 is a long noncoding mRNA. PCA3 does not encode a protein, but its mRNA transcripts from prostatic cytology can be detected and measured in urine.<xref ref-type="bibr" rid="article-144254.r73">[73]</xref>&#x000a0;The PCA3 gene is overexpressed in 95% of primary prostate cancer specimens but not in benign prostate tissue.<xref ref-type="bibr" rid="article-144254.r74">[74]</xref><xref ref-type="bibr" rid="article-144254.r75">[75]</xref>&#x000a0;</p>
        <p>Reverse transcription polymerase chain reaction (RT-PCR) evaluation revealed that PCA3 performs better compared to PSA in identifying prostatic malignancy.<xref ref-type="bibr" rid="article-144254.r76">[76]</xref><xref ref-type="bibr" rid="article-144254.r77">[77]</xref>&#x000a0;Recently, with the advent of a transcription-mediated amplification assay, there has been an improved sensitivity compared to RT-PCR.<xref ref-type="bibr" rid="article-144254.r78">[78]</xref></p>
        <p>The commercial assay of PCA3 was FDA-approved in the United States in 2012 to assist decision-making in men aged 50 and older with a previous negative biopsy. The European Association of Urology also recommends this test.&#x000a0;A urine sample for PCA3 testing is obtained immediately after a prostate massage or DRE. Substantial research on the diagnostic value of PCA3 in post-prostatic massage urine has been performed, and all studies have shown that the PCA3 scores closely match the likelihood of a positive biopsy.<xref ref-type="bibr" rid="article-144254.r79">[79]</xref><xref ref-type="bibr" rid="article-144254.r80">[80]</xref><xref ref-type="bibr" rid="article-144254.r81">[81]</xref>&#x000a0;Unlike PSA, PCA3 levels are independent of prostate size.<xref ref-type="bibr" rid="article-144254.r82">[82]</xref></p>
        <p>Studies have reported a 14% positive biopsy rate if PCA3 levels are below 5, compared to 70% when the PCA3 assay is &#x0003e;100.<xref ref-type="bibr" rid="article-144254.r80">[80]</xref>&#x000a0;PCA3 has been proven to have different sensitivity, specificity, and predictive values when choosing alternative cutoffs. The FDA used a threshold of 25 for its approval. Studies involving large patient cohorts have demonstrated the superiority of PCA3 over PSA alone for diagnosing prostate cancer.<xref ref-type="bibr" rid="article-144254.r83">[83]</xref><xref ref-type="bibr" rid="article-144254.r84">[84]</xref><xref ref-type="bibr" rid="article-144254.r85">[85]</xref>&#x000a0;PCA3 has been incorporated with other clinical parameters in various nomograms,&#x000a0;such as the&#x000a0;web-based PCPT risk calculator, to analyze the chance of a positive biopsy.<xref ref-type="bibr" rid="article-144254.r86">[86]</xref></p>
        <p><bold><italic toggle="yes">TMPRSS2-ERG</italic>&#x000a0;gene fusions and My Prostate Score 2:&#x000a0;</bold>With the discovery of gene fusions in prostate malignancy, considerable research has been performed to harness its utility as prostate cancer biomarkers. The most common gene alteration involved with prostate cancer is the fusion of the androgen-regulated gene transmembrane protease, serine 2 (<italic toggle="yes">TMPRSS2</italic>), with the N-terminal deleted ERG coding region.<xref ref-type="bibr" rid="article-144254.r87">[87]</xref>&#x000a0;Between 50%&#x000a0;and 60% of patients with prostate cancer of European ancestry have this gene fusion, which results in the oncogenic activation of ERG.<xref ref-type="bibr" rid="article-144254.r88">[88]</xref>&#x000a0;The use of gene fusion was most significant when combined with other biomarkers, such as PCA3.</p>
        <p>A multicentric study&#x000a0;involving 1312 men compared post-DRE urine levels of TMPRSS2:ERG to PCA3 with serum PSA.&#x000a0;The study demonstrated the clear superiority of the panel of TMPRSS2:ERG with PCA3 in detecting clinically significant malignancy at biopsy.<xref ref-type="bibr" rid="article-144254.r89">[89]</xref>&#x000a0;An assay developed by the University of Michigan, My Prostate Score 2 (MPS2), combines serum PSA, urine PCA3, and urine TMPRSS2:ERG gene fusion to estimate the probability of identifying prostate malignancy on biopsy and the likelihood of aggressive disease.<xref ref-type="bibr" rid="article-144254.r90">[90]</xref>&#x000a0;PCA3 and TMPRSS2:ERG gene fusion is presently incorporated into a PCPT risk calculator for decision-making for prostate biopsy in patients with persistently (at least 2) elevated levels of&#x000a0;PSA to avoid unnecessary biopsies safely.<xref ref-type="bibr" rid="article-144254.r86">[86]</xref>&#x000a0;The NCCN has included MPS2 as one of its recommended prostate cancer risk stratification bioassays.</p>
        <p><bold>Select MDx:&#x000a0;</bold>The Select MDx is an RT-PCR assay analyzing urine specimens after DRE along with other risk factors for early detection of prostate malignancy and decision-making regarding biopsy. This 3-gene panel assay has enhanced the identification of high-grade cancer by integrating HOXC6, TDRD1, and DLX1 mRNA levels in urine with other clinical indicators. In addition, Van Neste et al have validated it with other clinical decision-making tools, such as the PCA3 assay and PCPT risk calculator.<xref ref-type="bibr" rid="article-144254.r91">[91]</xref>&#x000a0;The NCCN has identified Select MDx as one of its recommended prostate cancer risk stratification assays.</p>
        <p><bold>Annexin A3:&#x000a0;</bold>Annexin A3, a calcium-dependent phospholipid-binding protein, is found to be negatively associated with the detection of prostate malignancy when present in urine. Researchers have evaluated the utility of analyzing Annexin A3 levels in post-DRE urine as a stand-alone or in conjunction with serum PSA for clinical decision-making before a prostate needle biopsy.<xref ref-type="bibr" rid="article-144254.r92">[92]</xref>&#x000a0;</p>
        <p>Investigators showed that Annexin A3 enhanced PSA's ability to predict malignancy in needle biopsy with an area under the curve (AUC) of 0.81. Cao et al studied a multiplex assay combining urine annexin A3, PCA3, TMPRSS2: ERG, and sarcosine for prostate biopsy decision-making.<xref ref-type="bibr" rid="article-144254.r93">[93]</xref> The multi-marker assay was accurate, with an AUC of 0.84 in patients with a PSA of 4 to 10 ng/mL.<xref ref-type="bibr" rid="article-144254.r93">[93]</xref></p>
        <p><bold>ExoDx p</bold><bold>rostate intelliscore:&#x000a0;</bold>Exosomes are tiny extracellular vesicles (40-150 nm) released by various cell types, including cancerous cells. They contain lipids, proteins, and nucleic acids. Prostate-derived exosomes serve as diagnostic and prognostic biomarkers as they are a source of proteins and microRNA.<xref ref-type="bibr" rid="article-144254.r94">[94]</xref><xref ref-type="bibr" rid="article-144254.r95">[95]</xref>&#x000a0;Urinary exosome analysis offers benefits, including stable exosomes owing to their exosomal lipid bilayer, which protects the genetic content from enzymatic destruction. No unpleasant prostatic massage is needed before collecting the sample, and the test can be performed at home with the specimen mailed directly to the laboratory by the patient, saving staff time and paperwork. Exosomal RNA and protein content that are tested may be superior to less stable, chemical, nongenetic-based biomarkers.</p>
        <p>ExoDx prostate intelliscore is a urine exosomal RNA-based assay to assess the expression of the prooncogenic genes <italic toggle="yes">ERG</italic>,<italic toggle="yes"> PCA3</italic>, and <italic toggle="yes">SPDEF</italic> and generate a score. The test is recommended for males older than&#x000a0;50 with a PSA of 2 to 10 ng/mL who are being evaluated for a preliminary biopsy. This test is used with other standards of care criteria to assess the likelihood of Gleason 7 and above prostate cancer on an initial biopsy.<xref ref-type="bibr" rid="article-144254.r96">[96]</xref><xref ref-type="bibr" rid="article-144254.r97">[97]</xref>&#x000a0;</p>
        <p>This assay helps safely reduce unnecessary biopsies. This score predicted high-grade cancer (Gleason 7 and above) with a negative predictive value of &#x0003e;90%.<xref ref-type="bibr" rid="article-144254.r96">[96]</xref>&#x000a0;The test is far more patient-friendly compared to similar bioassays as it does not require a digital rectal exam or prostatic massage, unlike previous urine-based tests for prostate cancer. The kit is designed for home use and can be mailed directly to the diagnostic laboratory by the patient, making it particularly useful for patients without a rectum for digital prostatic massage or those for whom the procedure is not feasible.</p>
        <p>A large cohort study involving 774 patients in the United States found that the ExoDx assay, in conjunction with standards of care features, outperformed the ExoDx assay or standards of care variables when used alone in predicting the presence of Gleason grade 7 or above and negative biopsies.<xref ref-type="bibr" rid="article-144254.r96">[96]</xref>&#x000a0;Several exosomal metabolites, including survivin and claudin 3, have also been higher in the plasma of patients with prostate cancer.<xref ref-type="bibr" rid="article-144254.r98">[98]</xref><xref ref-type="bibr" rid="article-144254.r99">[99]</xref><xref ref-type="bibr" rid="article-144254.r100">[100]</xref>&#x000a0;ExoDx is also one of the tests recommended by the NCCN for prostate cancer risk stratification bioassay testing.</p>
        <p><bold>Prostarix risk score:</bold>&#x000a0;Prostarix risk score&#x000a0;is a urine-based assay that assists clinicians in decision-making regarding biopsy in a grey zone, such as negative DRE or a mildly elevated PSA level setting.<xref ref-type="bibr" rid="article-144254.r101">[101]</xref>&#x000a0;The assay quantitatively analyses 4-metabolites, sarcosine, alanine, glycine, and glutamate, in urine employing liquid chromatography-mass spectrometry.<italic toggle="yes">&#x000a0;</italic>The quantitative analysis of these amino acids helps to calculate the risk score and detect malignancy-related metabolic abnormalities. Studies have shown that the panel's performance in diagnosing prostate cancer (AUC=0.64) was superior to that of serum PSA (AUC=0.53) and the PCPT calculator alone (AUC=0.61).<xref ref-type="bibr" rid="article-144254.r102">[102]</xref>&#x000a0;</p>
        <p><bold>Prostate cancer cell lines in urine:&#x000a0;</bold>Prostate cancer cells can be found in post-DRE urine using multiplex immunofluorescence cytology staining for AMACR, Nucleolin, DAPI, and Nkx3.1. In a study involving a cohort of 50 patients, this method achieved a sensitivity of 36% and a specificity of 100%.<xref ref-type="bibr" rid="article-144254.r103">[103]</xref>&#x000a0;Immunohistochemistry also studies cell lines for ERG, AMACR, and Prostein (prostate epithelium-specific).<xref ref-type="bibr" rid="article-144254.r104">[104]</xref>&#x000a0;In a cohort of 63 individuals, this assay has a sensitivity of 64% and a specificity of 68.8% for diagnosing prostate cancer.<xref ref-type="bibr" rid="article-144254.r104">[104]</xref>&#x000a0;The NCCN has recognized the PHI, 4K score, ExoDx intelliscore, My Prostate Score, Select MDx, and ConfirmMDx (a tissue-based confirmation test).</p>
        <p>
<bold>How To Best Use Risk-Stratification Bioassays in Prostate Cancer Screening</bold>
</p>
        <p>Although their precise role in prostate cancer screening is still being determined, experts have suggested that risk-stratification bioassays are most helpful in patients with persistently elevated&#x000a0;PSA levels who are low-risk, borderline, or equivocal cases. In such cases, the result, if negative, is used to help make a clinical decision not to pursue further prostate cancer diagnostic testing or screening procedures immediately.<xref ref-type="bibr" rid="article-144254.r1">[1]</xref><xref ref-type="bibr" rid="article-144254.r2">[2]</xref>&#x000a0;Regardless of the test used, about 75% test positive. This result is not an indication of cancer, only that their risk analysis biomarker assay could not safely exclude a possible clinically significant cancer. The majority of these patients ultimately demonstrate negative biopsies and do not have prostate cancer.</p>
        <p>Risk stratification bioassays for prostate cancer may also have a role in monitoring patients on active surveillance and those with high-grade prostatic intraepithelial neoplasia or atypical small acinar proliferation, which are considered premalignant.<xref ref-type="bibr" rid="article-144254.r1">[1]</xref><xref ref-type="bibr" rid="article-144254.r105">[105]</xref><xref ref-type="bibr" rid="article-144254.r106">[106]</xref><xref ref-type="bibr" rid="article-144254.r107">[107]</xref><xref ref-type="bibr" rid="article-144254.r108">[108]</xref><xref ref-type="bibr" rid="article-144254.r109">[109]</xref>&#x000a0;The risk calculators can be accessed from the following websites:</p>
        <list list-type="bullet">
          <list-item>
            <p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://riskcalc.org/PCPTRC/">Prostate Cancer Prevention Trial Risk Calculator 2.0</ext-link> (UT Health San Antonio)</p>
          </list-item>
          <list-item>
            <p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.prostatecancer-riskcalculator.com/seven-prostate-cancer-risk-calculators">The Prostate Cancer Risk Calculators</ext-link> (SWOP&#x02014;The Prostate Cancer Research Foundation, Reeuwijk)</p>
          </list-item>
          <list-item>
            <p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.med.unc.edu/menshealth/prostate-cancer-prevention-risk-calculator/">Prostate Cancer Prevention Risk Calculator</ext-link> (UNC School of Medicine)</p>
          </list-item>
          <list-item>
            <p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://med.stanford.edu/ucil/nomogram.html">SPCC Risk Calculator</ext-link> (Stanford Medicine)</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-144254.s7" sec-type="Testing Procedures">
        <title>Testing Procedures</title>
        <p>An abnormally elevated PSA in a grey zone (4-10 ng/mL) warrants a repeat PSA and a DRE. Patients whose repeat PSA and DRE are normal may continue with routine follow-ups. However, if the repeat PSA is elevated or the DRE is abnormal, and a prostate malignancy is suspected, biomarkers aid in the decision-making regarding continuing observation versus proceeding directly to a biopsy. Various biomarkers, including PHI, 4K score, PCA3, ExoDx Intelliscore, and Select MDx, help make this decision by identifying patients at low risk.</p>
        <p>Biomarkers may be used alone or as a variable in risk analysis calculators. For example, if a biopsy was already performed with a negative result, biomarkers can assist in deciding when or if to repeat the biopsy.&#x000a0;According to the NCCN recommendations, if the initial biopsy is reported as atypia, suspicious for cancer, or high-grade prostatic intraepithelial neoplasia, biomarkers that improve the specificity of screening, including fPSA, 4K score, PHI, PCA3, Exo Dx Prostate score, and MPS2, may be considered (see <bold>Table.&#x000a0;</bold>Urinary Biomarkers). Alternatively, this subset of patients may proceed with a multiparametric prostate MRI if no prior prostatic study is available.</p>
        <p>Most urinary biomarker assays are performed after prostatic manipulation (massage), except the ExoDx EPI score, which is not required. Studies have shown that a DRE can enrich urinary biomarkers and enhance yield, the first void after a DRE is obtained and analyzed. Following a prostate massage, the first 10&#x000a0;to 50 mL of urine that is voided are centrifuged at 1000&#x000a0;to 2000 rotations per minute to produce precipitates of urine that may contain prostate cancer cells, cell fragments,&#x000a0;and&#x000a0;various biomolecules such as DNA, RNA, and proteins from these cells. Free proteins, DNA, RNA, other tiny molecules, and exosomes&#x000a0;are all detected in the supernatant.</p>
        <p>Exosome precipitation occurs as a result of further ultracentrifugation of the supernatant. The ExoDx Intelliscore is far more patient-friendly compared to other biomarkers, as it does not require a digital rectal exam or prostatic massage. Unlike other urine-based tests for prostate cancer, it is available as a kit for home usage that patients can mail directly back to the diagnostic laboratory.<xref ref-type="bibr" rid="article-144254.r73">[73]</xref>&#x000a0;</p>
        <table-wrap id="article-144254.table1" position="float" orientation="portrait">
          <caption>
            <title>Table. Urinary Biomarkers</title>
          </caption>
          <table style="width: 800px;" border="1" cellspacing="1" cellpadding="2">
            <tbody>
              <tr style="height: 49px;">
                <td style="width: 132px; height: 49px;" rowspan="1" colspan="1">
<bold>Assay Name</bold>
</td>
                <td style="width: 119.913px; height: 49px;" rowspan="1" colspan="1">
<bold>Requires Prostatic Manipulation/Digital Rectal Exam</bold>
</td>
                <td style="width: 135.087px; height: 49px;" rowspan="1" colspan="1">
<bold>Specimen Used&#x000a0;</bold>
</td>
              </tr>
              <tr style="height: 28px;">
                <td style="width: 132px; height: 28px;" rowspan="1" colspan="1">PCA3</td>
                <td style="width: 119.913px; height: 28px;" rowspan="1" colspan="1">Post-DRE void</td>
                <td style="width: 135.087px; height: 28px;" rowspan="1" colspan="1">Whole urine/precipitate&#x000a0;</td>
              </tr>
              <tr style="height: 44.8635px;">
                <td style="width: 132px; height: 44.8635px;" rowspan="1" colspan="1">
<p>My Prostate score of 2</p>
<p>(PCA3, TMPRSS2-ERG)</p>
</td>
                <td style="width: 119.913px; height: 44.8635px;" rowspan="1" colspan="1">Post-DRE void</td>
                <td style="width: 135.087px; height: 44.8635px;" rowspan="1" colspan="1">Whole urine</td>
              </tr>
              <tr style="height: 29px;">
                <td style="width: 132px; height: 29px;" rowspan="1" colspan="1">Annexin A3</td>
                <td style="width: 119.913px; height: 29px;" rowspan="1" colspan="1">Post-DRE void</td>
                <td style="width: 135.087px; height: 29px;" rowspan="1" colspan="1">Precipitate</td>
              </tr>
              <tr style="height: 35px;">
                <td style="width: 132px; height: 35px;" rowspan="1" colspan="1">
<p>ExoDx Intelliscore</p>
</td>
                <td style="width: 119.913px; height: 35px;" rowspan="1" colspan="1">
<p>Not necessary/not recommended&#x000a0;</p>
</td>
                <td style="width: 135.087px; height: 35px;" rowspan="1" colspan="1">Precipitate</td>
              </tr>
              <tr style="height: 27px;">
                <td style="width: 132px; height: 27px;" rowspan="1" colspan="1">
<p>DLX1, HOXC6</p>
</td>
                <td style="width: 119.913px; height: 27px;" rowspan="1" colspan="1">Post-DRE void</td>
                <td style="width: 135.087px; height: 27px;" rowspan="1" colspan="1">Precipitate</td>
              </tr>
              <tr style="height: 35px;">
                <td style="width: 132px; height: 35px;" rowspan="1" colspan="1">
<p>Prostate cancer cell lines</p>
</td>
                <td style="width: 119.913px; height: 35px;" rowspan="1" colspan="1">Post-DRE void</td>
                <td style="width: 135.087px; height: 35px;" rowspan="1" colspan="1">Precipitate</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="article-144254.s8" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Serum PSA is the gold standard during initial investigation for initial prostate cancer screening and early detection. PSA as a biomarker is a sensitive tool, but its specificity is low. Various benign conditions, such as benign prostatic hyperplasia and prostatitis, and manipulations, such as DRE, biopsy, and catheterization, can increase PSA levels. Consequently, diagnosis with PSA alone can lead to overdiagnosis and unwanted biopsies, adding pressure on healthcare systems and causing unnecessary patient anxiety.</p>
        <p>A PSA level eliminating the risk of prostate cancer does not exist. Instead, the likelihood of prostate cancer and an aggressive disease increases as the PSA rises. Instead of using an absolute PSA level to establish if a prostate biopsy is necessary, the clinician should consider other variables, including prostate volume, inflammation, medications, patient age, life expectancy, prior PSA levels, and comorbidities.</p>
        <p>Prostate cancer biomarkers assist the clinician in decision-making in patients with PSA levels in the grey zone of 4&#x000a0;to 10 ng/mL to safely avoid unnecessary biopsies. The biomarkers can also predict clinically significant tumors and help tailor the treatment regimen. Biomarker assays are employed in a grey zone PSA level setting with a negative DRE. Biomarkers allow clinicians to discuss better-informed decision-making with patients.</p>
        <p>Various additional tools, such as PSA derivatives, PSA kinetics, PSA molecular forms, PSA density calculations, and risk stratification biomarkers, can be used as standalone or in multiplex panels to arrive at an informed decision in equivocal situations. The new prostate cancer risk-stratification biomarkers are intended to assist the clinician in educating and informing patients for optimal shared decision-making.</p>
      </sec>
      <sec id="article-144254.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The past decade saw a paradigm shift in the management of prostate malignancy. With advances in diagnostics, imaging, genetics, and metabolomics, the evaluation and management of prostate malignancy have become even more complex. However, there needs to be more consensus on various diagnostic and treatment protocols, and different expert guidelines fall short of offering concrete recommendations. Multidisciplinary agreement and coordination are crucial for improving prostate cancer outcomes.</p>
        <p>To provide the patient with the best care possible, a team of specially qualified nurses, technicians, general practitioners, pharmacists, genetic counselors, psychotherapists, oncologists, radiologists, urologists, and allied healthcare workers must collaborate. The team must be able to educate, enlighten, and guide the patient for optimal care while avoiding unnecessary overdiagnosis and overtreatment.&#x000a0;In addition, prostate cancer screening should follow published guideline recommendations and include shared decision-making techniques and procedures. Any team member who notes any departure from guidelines should be empowered to communicate their concerns to the team, including the clinicians.</p>
        <p>Optimal use of risk stratification biomarker assays for prostate cancer can significantly reduce unnecessary diagnostic procedures and treatments. The healthcare team should be familiar with implementing these assays when appropriate and help educate the patient and family when necessary or requested.&#x000a0;The screening, diagnosis, and treatment must be individualized based on age, high-risk characteristics, comorbid conditions, life expectancy, and personal preferences. The patient must be empowered to make apt decisions through interdisciplinary team consultations and proper communication between the patient and the clinicians. Overtreatment, due to side effects, can cause harm to the patient, adversely affecting his quality of life and placing the patient under undue psychological distress. Eligible patients may be spared from such adversities by utilizing active surveillance protocols.</p>
      </sec>
      <sec id="article-144254.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=144254&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=144254">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/144254/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=144254">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-144254.s11">
        <title>References</title>
        <ref id="article-144254.r1">
          <label>1</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Leslie</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Soon-Sutton</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>R I</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sajjad</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Skelton</surname>
                <given-names>WP</given-names>
              </name>
            </person-group>
            <chapter-title>Prostate Cancer</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>11</month>
            <day>13</day>
            <pub-id pub-id-type="pmid">29261872</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r2">
          <label>2</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Jain</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Sapra</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <chapter-title>Prostate Cancer Screening</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>10</month>
            <day>26</day>
            <pub-id pub-id-type="pmid">32310541</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jansson</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Akre</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Garmo</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bill-Axelson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Adolfsson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stattin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bratt</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Concordance of tumor differentiation among brothers with prostate cancer.</article-title>
            <source>Eur Urol</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>62</volume>
            <issue>4</issue>
            <fpage>656</fpage>
            <page-range>656-61</page-range>
            <pub-id pub-id-type="pmid">22386193</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bratt</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Drevin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Akre</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Garmo</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Stattin</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Family History and Probability of Prostate Cancer, Differentiated by Risk Category: A Nationwide Population-Based Study.</article-title>
            <source>J Natl Cancer Inst</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>108</volume>
            <issue>10</issue>
            <pub-id pub-id-type="pmid">27400876</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Amin Al Olama</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dadaev</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hazelett</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Leongamornlert</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Saunders</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Stephens</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cieza-Borrella</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Whitmore</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Benlloch Garcia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Giles</surname>
                <given-names>GG</given-names>
              </name>
              <name>
                <surname>Southey</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Fitzgerald</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gronberg</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wiklund</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Aly</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Henderson</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Schumacher</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Haiman</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Schleutker</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wahlfors</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tammela</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Nordestgaard</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Key</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Travis</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Neal</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Donovan</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Hamdy</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Pharoah</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pashayan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Khaw</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Stanford</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Thibodeau</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Mcdonnell</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Schaid</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Maier</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vogel</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Luedeke</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Herkommer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kibel</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Cybulski</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Woko&#x00142;orczyk</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kluzniak</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Cannon-Albright</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Brenner</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Butterbach</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Arndt</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Sellers</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Slavov</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kaneva</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mitev</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Batra</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Clements</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Spurdle</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Teixeira</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Paulo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Maia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pandha</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Michael</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kierzek</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Govindasami</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Guy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lophatonanon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Muir</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Vi&#x000f1;uela</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>AA</given-names>
              </name>
              <collab>PRACTICAL Consortium</collab>
              <collab>COGS-CRUK GWAS-ELLIPSE (Part of GAME-ON) Initiative</collab>
              <collab>Australian Prostate Cancer BioResource</collab>
              <collab>UK Genetic Prostate Cancer Study Collaborators</collab>
              <collab>UK ProtecT Study Collaborators</collab>
              <name>
                <surname>Freedman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Conti</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Easton</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Coetzee</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Eeles</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Kote-Jarai</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans.</article-title>
            <source>Hum Mol Genet</source>
            <year>2015</year>
            <month>Oct</month>
            <day>01</day>
            <volume>24</volume>
            <issue>19</issue>
            <fpage>5589</fpage>
            <page-range>5589-602</page-range>
            <pub-id pub-id-type="pmid">26025378</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Olumi</surname>
                <given-names>AF</given-names>
              </name>
            </person-group>
            <article-title>Commentary on "identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array." Eeles RA, Olama AA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, Ghoussaini M, Luccarini C, Dennis J, Jugurnauth-Little S, Dadaev T, Neal DE, Hamdy FC, Donovan JL, Muir K, Giles GG, Severi G, Wiklund F, Gronberg H, Haiman CA, Schumacher F, Henderson BE, Le Marchand L, Lindstrom S, Kraft P, Hunter DJ, Gapstur S, Chanock SJ, Berndt SI, Albanes D, Andriole G, Schleutker J, Weischer M, Canzian F, Riboli E, Key TJ, Travis RC, Campa D, Ingles SA, John EM, Hayes RB, Pharoah PD, Pashayan N, Khaw KT, Stanford JL, Ostrander EA, Signorello LB, Thibodeau SN, Schaid D, Maier C, Vogel W, Kibel AS, Cybulski C, Lubinski J, Cannon-Albright L, Brenner H, Park JY, Kaneva R, Batra J, Spurdle AB, Clements JA, Teixeira MR, Dicks E, Lee A, Dunning AM, Baynes C, Conroy D, Maranian MJ, Ahmed S, Govindasami K, Guy M, Wilkinson RA, Sawyer EJ, Morgan A, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As NJ, Woodhouse CJ, Thompson A, Dudderidge T, Ogden C, Cooper CS, Lophatananon A, Cox A, Southey MC, Hopper JL, English DR, Aly M, Adolfsson J, Xu J, Zheng SL, Yeager M, Kaaks R, Diver WR, Gaudet MM, Stern MC, Corral R, Joshi AD, Shahabi A, Wahlfors T, Tammela TL, Auvinen A, Virtamo J, Klarskov P, Nordestgaard BG, R&#x000f8;der MA, Nielsen SF, Bojesen SE, Siddiq A, Fitzgerald LM, Kolb S, Kwon EM, Karyadi DM, Blot WJ, Zheng W, Cai Q, McDonnell SK, Rinckleb AE, Drake B, Colditz G, Wokolorczyk D, Stephenson RA, Teerlink C, Muller H, Rothenbacher D, Sellers TA, Lin HY, Slavov C, Mitev V, Lose F, Srinivasan S, Maia S, Paulo P, Lange E, Cooney KA, Antoniou AC, Vincent D, Bacot F, Tessier DC; COGS-Cancer Research UK GWAS-ELLIPSE (part of GAME-ON) Initiative; Australian Prostate Cancer Bioresource; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK ProtecT (Prostate testing for cancer and Treatment) Study.</article-title>
            <source>Urol Oncol</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>32</volume>
            <issue>2</issue>
            <fpage>211</fpage>
            <pub-id pub-id-type="pmid">24445293</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schumacher</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>Olama</surname>
                <given-names>AAA</given-names>
              </name>
              <name>
                <surname>Berndt</surname>
                <given-names>SI</given-names>
              </name>
              <name>
                <surname>Benlloch</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Saunders</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Dadaev</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Leongamornlert</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Anokian</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cieza-Borrella</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Goh</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Brook</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Sheng</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Fachal</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Dennis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tyrer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Muir</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lophatananon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stevens</surname>
                <given-names>VL</given-names>
              </name>
              <name>
                <surname>Gapstur</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Tangen</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Goodman</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Batra</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chambers</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moya</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Clements</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Horvath</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tilley</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Risbridger</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Gronberg</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Aly</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nordstr&#x000f6;m</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pharoah</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pashayan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Schleutker</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tammela</surname>
                <given-names>TLJ</given-names>
              </name>
              <name>
                <surname>Sipeky</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Auvinen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Albanes</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Weinstein</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wolk</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>H&#x000e5;kansson</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>West</surname>
                <given-names>CML</given-names>
              </name>
              <name>
                <surname>Dunning</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Burnet</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mucci</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Giovannucci</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Andriole</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Cussenot</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Cancel-Tassin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Koutros</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Beane Freeman</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Sorensen</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Orntoft</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>Borre</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maehle</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Grindedal</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Neal</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Donovan</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Hamdy</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Travis</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Key</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Hamilton</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Fleshner</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Finelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ingles</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Stern</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Rosenstein</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Kerns</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Ostrer</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mao</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Giles</surname>
                <given-names>GG</given-names>
              </name>
              <name>
                <surname>Southey</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>MacInnis</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>FitzGerald</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Kibel</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Drake</surname>
                <given-names>BF</given-names>
              </name>
              <name>
                <surname>Vega</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>G&#x000f3;mez-Caama&#x000f1;o</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Szulkin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Eklund</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kogevinas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Llorca</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Casta&#x000f1;o-Vinyals</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Penney</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Stampfer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Sellers</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Stanford</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Cybulski</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wokolorczyk</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lubinski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ostrander</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Geybels</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Nordestgaard</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Nielsen</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Weischer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bisbjerg</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>R&#x000f8;der</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Iversen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Brenner</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cuk</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Holleczek</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Maier</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Luedeke</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schnoeller</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Logothetis</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>John</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Teixeira</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Paulo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cardoso</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Neuhausen</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Steele</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>De Ruyck</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>De Meerleer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ost</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Razack</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Teo</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Newcomb</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Lessel</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gamulin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kulis</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kaneva</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Usmani</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Singhal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Slavov</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mitev</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Parliament</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Claessens</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Joniau</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Van den Broeck</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Larkin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Townsend</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Aukim-Hastie</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gago-Dominguez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Castelao</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Martinez</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Roobol</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Jenster</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>van Schaik</surname>
                <given-names>RHN</given-names>
              </name>
              <name>
                <surname>Menegaux</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Truong</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Koudou</surname>
                <given-names>YA</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Khaw</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Cannon-Albright</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pandha</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Michael</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Thibodeau</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>McDonnell</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Schaid</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Lindstrom</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Turman</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hunter</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Riboli</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Siddiq</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Canzian</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kolonel</surname>
                <given-names>LN</given-names>
              </name>
              <name>
                <surname>Le Marchand</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hoover</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Machiela</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Cui</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Kraft</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Amos</surname>
                <given-names>CI</given-names>
              </name>
              <name>
                <surname>Conti</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Easton</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Wiklund</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Chanock</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Henderson</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Kote-Jarai</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Haiman</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Eeles</surname>
                <given-names>RA</given-names>
              </name>
              <collab>Profile Study</collab>
              <collab>Australian Prostate Cancer BioResource (APCB)</collab>
              <collab>IMPACT Study</collab>
              <collab>Canary PASS Investigators</collab>
              <collab>Breast and Prostate Cancer Cohort Consortium (BPC3)</collab>
              <collab>PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium</collab>
              <collab>Cancer of the Prostate in Sweden (CAPS)</collab>
              <collab>Prostate Cancer Genome-wide Association Study of Uncommon Susceptibility Loci (PEGASUS)</collab>
              <collab>Genetic Associations and Mechanisms in Oncology (GAME-ON)/Elucidating Loci Involved in Prostate Cancer Susceptibility (ELLIPSE) Consortium</collab>
            </person-group>
            <article-title>Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.</article-title>
            <source>Nat Genet</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>51</volume>
            <issue>2</issue>
            <fpage>363</fpage>
            <pub-id pub-id-type="pmid">30622367</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Giri</surname>
                <given-names>VN</given-names>
              </name>
              <name>
                <surname>Hegarty</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Hyatt</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>O'Leary</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Garcia</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Knudsen</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>Gomella</surname>
                <given-names>LG</given-names>
              </name>
            </person-group>
            <article-title>Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing.</article-title>
            <source>Prostate</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>79</volume>
            <issue>4</issue>
            <fpage>333</fpage>
            <page-range>333-339</page-range>
            <pub-id pub-id-type="pmid">30450585</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Giri</surname>
                <given-names>VN</given-names>
              </name>
              <name>
                <surname>Morgan</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Berchuck</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Hyatt</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Taplin</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Genetic testing in prostate cancer management: Considerations informing primary care.</article-title>
            <source>CA Cancer J Clin</source>
            <year>2022</year>
            <month>Jul</month>
            <volume>72</volume>
            <issue>4</issue>
            <fpage>360</fpage>
            <page-range>360-371</page-range>
            <pub-id pub-id-type="pmid">35201622</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pritchard</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Mateo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>De Sarkar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Abida</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Beltran</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Garofalo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gulati</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Carreira</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Eeles</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Elemento</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lonigro</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hussain</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chinnaiyan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vinson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Filipenko</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Garraway</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Taplin</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>AlDubayan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Beightol</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Morrissey</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nghiem</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Montgomery</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Casadei</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Berger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zehir</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vijai</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Scher</surname>
                <given-names>HI</given-names>
              </name>
              <name>
                <surname>Sawyers</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schultz</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kantoff</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Solit</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Robson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Van Allen</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Offit</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>de Bono</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>PS</given-names>
              </name>
            </person-group>
            <article-title>Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.</article-title>
            <source>N Engl J Med</source>
            <year>2016</year>
            <month>Aug</month>
            <day>04</day>
            <volume>375</volume>
            <issue>5</issue>
            <fpage>443</fpage>
            <page-range>443-53</page-range>
            <pub-id pub-id-type="pmid">27433846</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ewing</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Ray</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Lange</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Zuhlke</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Robbins</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Tembe</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Wiley</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Isaacs</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Johng</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Bizon</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gielzak</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Partin</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Shanmugam</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Izatt</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sinari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Craig</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Montie</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Carpten</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Isaacs</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Cooney</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>Germline mutations in HOXB13 and prostate-cancer risk.</article-title>
            <source>N Engl J Med</source>
            <year>2012</year>
            <month>Jan</month>
            <day>12</day>
            <volume>366</volume>
            <issue>2</issue>
            <fpage>141</fpage>
            <page-range>141-9</page-range>
            <pub-id pub-id-type="pmid">22236224</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lynch</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Kosoko-Lasaki</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Rendell</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Snyder</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>D'Amico</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Buxbaum</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Isaacs</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Loeb</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moul</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Powell</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Screening for familial and hereditary prostate cancer.</article-title>
            <source>Int J Cancer</source>
            <year>2016</year>
            <month>Jun</month>
            <day>01</day>
            <volume>138</volume>
            <issue>11</issue>
            <fpage>2579</fpage>
            <page-range>2579-91</page-range>
            <pub-id pub-id-type="pmid">26638190</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Page</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Bancroft</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Brook</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Assel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hassan Al Battat</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Chamberlain</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pope</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Raghallaigh</surname>
                <given-names>HN</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Rothwell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Maehle</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Grindedal</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mascarenhas</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>McKinley</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Side</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>van Asperen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vasen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kiemeney</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Ringelberg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Osther</surname>
                <given-names>PJS</given-names>
              </name>
              <name>
                <surname>Helfand</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Genova</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Oldenburg</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Cybulski</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wokolorczyk</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ong</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Huber</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Salinas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Feliubadal&#x000f3;</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Oosterwijk</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>van Zelst-Stams</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rosario</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Domchek</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Powers</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Buys</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>O'Toole</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ausems</surname>
                <given-names>MGEM</given-names>
              </name>
              <name>
                <surname>Schmutzler</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Rhiem</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Izatt</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tripathi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Teixeira</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Cardoso</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Foulkes</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Aprikian</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>van Randeraad</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Davidson</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Longmuir</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ruijs</surname>
                <given-names>MWG</given-names>
              </name>
              <name>
                <surname>Helderman van den Enden</surname>
                <given-names>ATJM</given-names>
              </name>
              <name>
                <surname>Adank</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Andrews</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Halliday</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Liljegren</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Carlsson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Azzabi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jobson</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Morton</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Shackleton</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Snape</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hanson</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tischkowitz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kirk</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Susman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chen-Shtoyerman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Spigelman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pachter</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ramon Y Cajal</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Zgajnar</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Brewer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gadea</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Brady</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>van Os</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Gallagher</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Johannsson</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Donaldson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barwell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nicolai</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Friedman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Obeid</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Greenhalgh</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Murthy</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Copakova</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Saya</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>McGrath</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cooke</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>R&#x000f8;nlund</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Richardson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Henderson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Teo</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Arun</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kast</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dias</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Aaronson</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Ardern-Jones</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bangma</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Castro</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Dearnaley</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Eccles</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Tricker</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Eyfjord</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Falconer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gronberg</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hamdy</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Stefansdottir</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Khoo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Lindeman</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Lubinski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Axcrona</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mikropoulos</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mitra</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Moynihan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rennert</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Suri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dudderidge</surname>
                <given-names>T</given-names>
              </name>
              <collab>IMPACT Study Collaborators</collab>
              <name>
                <surname>Offman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kote-Jarai</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Vickers</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lilja</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Eeles</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers.</article-title>
            <source>Eur Urol</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>76</volume>
            <issue>6</issue>
            <fpage>831</fpage>
            <page-range>831-842</page-range>
            <pub-id pub-id-type="pmid">31537406</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Breslow</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Dhom</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Drury</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Franks</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Gellei</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Lundberg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sparke</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sternby</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Tulinius</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France.</article-title>
            <source>Int J Cancer</source>
            <year>1977</year>
            <month>Nov</month>
            <day>15</day>
            <volume>20</volume>
            <issue>5</issue>
            <fpage>680</fpage>
            <page-range>680-8</page-range>
            <pub-id pub-id-type="pmid">924691</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Loeb</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sanda</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Broyles</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Bangma</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Partin</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Klee</surname>
                <given-names>GG</given-names>
              </name>
              <name>
                <surname>Slawin</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Marks</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>van Schaik</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Sokoll</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Cruz</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Mizrahi</surname>
                <given-names>IA</given-names>
              </name>
              <name>
                <surname>Catalona</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>The prostate health index selectively identifies clinically significant prostate cancer.</article-title>
            <source>J Urol</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>193</volume>
            <issue>4</issue>
            <fpage>1163</fpage>
            <page-range>1163-9</page-range>
            <pub-id pub-id-type="pmid">25463993</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Loeb</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Broyles</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Sanda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Klee</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Partin</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Sokoll</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Bangma</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>van Schaik</surname>
                <given-names>RHN</given-names>
              </name>
              <name>
                <surname>Slawin</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Marks</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Catalona</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer.</article-title>
            <source>BJU Int</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>120</volume>
            <issue>1</issue>
            <fpage>61</fpage>
            <page-range>61-68</page-range>
            <pub-id pub-id-type="pmid">27743489</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Borque-Fernando</surname>
                <given-names>&#x000c1;</given-names>
              </name>
              <name>
                <surname>Rubio-Briones</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Esteban</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Dong</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Calatrava</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>G&#x000f3;mez-Ferrer</surname>
                <given-names>&#x000c1;</given-names>
              </name>
              <name>
                <surname>G&#x000f3;mez-G&#x000f3;mez</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gil Fabra</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez-Garc&#x000ed;a</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez Gonz&#x000e1;lez</surname>
                <given-names>P&#x000c1;</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-Rodr&#x000ed;guez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rodrigo-Aliaga</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Herrera-Imbroda</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Soto-Villalba</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez-Breijo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hern&#x000e1;ndez-Ca&#x000f1;as</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Soto-Poveda</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>S&#x000e1;nchez-Rodr&#x000ed;guez</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Carrillo-George</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hern&#x000e1;ndez-Mart&#x000ed;nez</surname>
                <given-names>YE</given-names>
              </name>
              <name>
                <surname>Okrongly</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Role of the 4Kscore test as a predictor of reclassification in prostate cancer active surveillance.</article-title>
            <source>Prostate Cancer Prostatic Dis</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>84</fpage>
            <page-range>84-90</page-range>
            <pub-id pub-id-type="pmid">30108375</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gittelman</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Hertzman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bailen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Koziol</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Henderson</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Efros</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bidair</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ward</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study.</article-title>
            <source>J Urol</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>190</volume>
            <issue>1</issue>
            <fpage>64</fpage>
            <page-range>64-9</page-range>
            <pub-id pub-id-type="pmid">23416644</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McKiernan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Noerholm</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tadigotla</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Torkler</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sant</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Alter</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Donovan</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Skog</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>A urine-based Exosomal gene expression test stratifies risk of high-grade prostate Cancer in men with prior negative prostate biopsy undergoing repeat biopsy.</article-title>
            <source>BMC Urol</source>
            <year>2020</year>
            <month>Sep</month>
            <day>01</day>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>138</fpage>
            <pub-id pub-id-type="pmid">32873277</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sanda</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Howard</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Tomlins</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Sokoll</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Regan</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Groskopf</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chipman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Patil</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Salami</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Scherr</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Kagan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Srivastava</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Siddiqui</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Joon</surname>
                <given-names>AY</given-names>
              </name>
              <name>
                <surname>Bantis</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Chinnayian</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>JT</given-names>
              </name>
              <collab>and the EDRN-PCA3 Study Group</collab>
              <name>
                <surname>Bidair</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kibel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Lotan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Partin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Taneja</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer.</article-title>
            <source>JAMA Oncol</source>
            <year>2017</year>
            <month>Aug</month>
            <day>01</day>
            <volume>3</volume>
            <issue>8</issue>
            <fpage>1085</fpage>
            <page-range>1085-1093</page-range>
            <pub-id pub-id-type="pmid">28520829</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salami</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Laxman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Regan</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Rickman</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Scherr</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bueti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Siddiqui</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tomlins</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Chinnaiyan</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Sanda</surname>
                <given-names>MG</given-names>
              </name>
            </person-group>
            <article-title>Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer.</article-title>
            <source>Urol Oncol</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>31</volume>
            <issue>5</issue>
            <fpage>566</fpage>
            <page-range>566-71</page-range>
            <pub-id pub-id-type="pmid">21600800</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haese</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Trooskens</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Steyaert</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hessels</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Brawer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vlaeminck-Guillem</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ruffion</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tilki</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Schalken</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Groskopf</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Van Criekinge</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Multicenter Optimization and Validation of a 2-Gene mRNA Urine Test for Detection of Clinically Significant Prostate Cancer before Initial Prostate Biopsy.</article-title>
            <source>J Urol</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>202</volume>
            <issue>2</issue>
            <fpage>256</fpage>
            <page-range>256-263</page-range>
            <pub-id pub-id-type="pmid">31026217</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r23">
          <label>23</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>David</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>SW</given-names>
              </name>
            </person-group>
            <chapter-title>Prostate Specific Antigen</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2022</year>
            <month>11</month>
            <day>10</day>
            <pub-id pub-id-type="pmid">32491427</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Armitage</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Newling</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Appleyard</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>The value of the measurement of serum prostate specific antigen in patients with benign prostatic hyperplasia and untreated prostate cancer.</article-title>
            <source>Br J Urol</source>
            <year>1988</year>
            <month>Dec</month>
            <volume>62</volume>
            <issue>6</issue>
            <fpage>584</fpage>
            <page-range>584-9</page-range>
            <pub-id pub-id-type="pmid">2464397</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Etzioni</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Howlader</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Ankerst</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Penson</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Goodman</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>IM</given-names>
              </name>
            </person-group>
            <article-title>Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial.</article-title>
            <source>J Urol</source>
            <year>2005</year>
            <month>Sep</month>
            <volume>174</volume>
            <issue>3</issue>
            <fpage>877</fpage>
            <page-range>877-81</page-range>
            <pub-id pub-id-type="pmid">16093979</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dalton</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title>Elevated serum prostate-specific antigen due to acute bacterial prostatitis.</article-title>
            <source>Urology</source>
            <year>1989</year>
            <month>Jun</month>
            <volume>33</volume>
            <issue>6</issue>
            <fpage>465</fpage>
            <pub-id pub-id-type="pmid">2471345</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marks</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Andriole</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Fitzpatrick</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Schulman</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Roehrborn</surname>
                <given-names>CG</given-names>
              </name>
            </person-group>
            <article-title>The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations.</article-title>
            <source>J Urol</source>
            <year>2006</year>
            <month>Sep</month>
            <volume>176</volume>
            <issue>3</issue>
            <fpage>868</fpage>
            <page-range>868-74</page-range>
            <pub-id pub-id-type="pmid">16890642</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ercole</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Lange</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Mathisen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chiou</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Vessella</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>Prostatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer.</article-title>
            <source>J Urol</source>
            <year>1987</year>
            <month>Nov</month>
            <volume>138</volume>
            <issue>5</issue>
            <fpage>1181</fpage>
            <page-range>1181-4</page-range>
            <pub-id pub-id-type="pmid">2444720</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stamey</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hay</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>McNeal</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Freiha</surname>
                <given-names>FS</given-names>
              </name>
              <name>
                <surname>Redwine</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.</article-title>
            <source>N Engl J Med</source>
            <year>1987</year>
            <month>Oct</month>
            <day>08</day>
            <volume>317</volume>
            <issue>15</issue>
            <fpage>909</fpage>
            <page-range>909-16</page-range>
            <pub-id pub-id-type="pmid">2442609</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guess</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Heyse</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Gormley</surname>
                <given-names>GJ</given-names>
              </name>
            </person-group>
            <article-title>The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia.</article-title>
            <source>Prostate</source>
            <year>1993</year>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>31</fpage>
            <page-range>31-7</page-range>
            <pub-id pub-id-type="pmid">7678930</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r31">
          <label>31</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Salisbury</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Tadi</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <chapter-title>5&#x003b1;-Reductase Inhibitors</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>6</month>
            <day>8</day>
            <pub-id pub-id-type="pmid">32310390</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wei</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Barocas</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Carlsson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Coakley</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Eggener</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Etzioni</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fine</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Kirkby</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Konety</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Miner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Moses</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nissenberg</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Pinto</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Salami</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Souter</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening.</article-title>
            <source>J Urol</source>
            <year>2023</year>
            <month>Jul</month>
            <volume>210</volume>
            <issue>1</issue>
            <fpage>46</fpage>
            <page-range>46-53</page-range>
            <pub-id pub-id-type="pmid">37096582</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wei</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Barocas</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Carlsson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Coakley</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Eggener</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Etzioni</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fine</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Kirkby</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Konety</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Miner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Moses</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nissenberg</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Pinto</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Salami</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Souter</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>Early Detection of Prostate Cancer: AUA/SUO Guideline Part II: Considerations for a Prostate Biopsy.</article-title>
            <source>J Urol</source>
            <year>2023</year>
            <month>Jul</month>
            <volume>210</volume>
            <issue>1</issue>
            <fpage>54</fpage>
            <page-range>54-63</page-range>
            <pub-id pub-id-type="pmid">37096575</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hugosson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Roobol</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>M&#x000e5;nsson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tammela</surname>
                <given-names>TLJ</given-names>
              </name>
              <name>
                <surname>Zappa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nelen</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kwiatkowski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lujan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Carlsson</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Talala</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Lilja</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Denis</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Recker</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Paez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Puliti</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Villers</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rebillard</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Kilpel&#x000e4;inen</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Stenman</surname>
                <given-names>UH</given-names>
              </name>
              <name>
                <surname>Godtman</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Stinesen Kollberg</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Moss</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Kujala</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Taari</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Huber</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>van der Kwast</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Heijnsdijk</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Bangma</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>De Koning</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Schr&#x000f6;der</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Auvinen</surname>
                <given-names>A</given-names>
              </name>
              <collab>ERSPC investigators</collab>
            </person-group>
            <article-title>A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer.</article-title>
            <source>Eur Urol</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>76</volume>
            <issue>1</issue>
            <fpage>43</fpage>
            <page-range>43-51</page-range>
            <pub-id pub-id-type="pmid">30824296</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fr&#x000e5;nlund</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>M&#x000e5;nsson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Godtman</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Aus</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Holmberg</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kollberg</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Lodding</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pihl</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Stranne</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lilja</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hugosson</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Results from 22 years of Followup in the G&#x000f6;teborg Randomized Population-Based Prostate Cancer Screening Trial.</article-title>
            <source>J Urol</source>
            <year>2022</year>
            <month>Aug</month>
            <volume>208</volume>
            <issue>2</issue>
            <fpage>292</fpage>
            <page-range>292-300</page-range>
            <pub-id pub-id-type="pmid">35422134</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Page</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Giovannucci</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Family history of prostate and breast cancer and the risk of prostate cancer in the PSA era.</article-title>
            <source>Prostate</source>
            <year>2008</year>
            <month>Oct</month>
            <day>01</day>
            <volume>68</volume>
            <issue>14</issue>
            <fpage>1582</fpage>
            <page-range>1582-91</page-range>
            <pub-id pub-id-type="pmid">18646000</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grill</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fallah</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Leach</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Freedland</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hemminki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ankerst</surname>
                <given-names>DP</given-names>
              </name>
            </person-group>
            <article-title>Incorporation of detailed family history from the Swedish Family Cancer Database into the PCPT risk calculator.</article-title>
            <source>J Urol</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>193</volume>
            <issue>2</issue>
            <fpage>460</fpage>
            <page-range>460-5</page-range>
            <pub-id pub-id-type="pmid">25242395</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barber</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gerke</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Markt</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Peisch</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Ahearn</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Giovannucci</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Parmigiani</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mucci</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Family History of Breast or Prostate Cancer and Prostate Cancer Risk.</article-title>
            <source>Clin Cancer Res</source>
            <year>2018</year>
            <month>Dec</month>
            <day>01</day>
            <volume>24</volume>
            <issue>23</issue>
            <fpage>5910</fpage>
            <page-range>5910-5917</page-range>
            <pub-id pub-id-type="pmid">30082473</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ren</surname>
                <given-names>ZJ</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Ren</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Dong</surname>
                <given-names>Q</given-names>
              </name>
            </person-group>
            <article-title>First-degree family history of breast cancer is associated with prostate cancer risk: a systematic review and meta-analysis.</article-title>
            <source>BMC Cancer</source>
            <year>2019</year>
            <month>Sep</month>
            <day>02</day>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>871</fpage>
            <pub-id pub-id-type="pmid">31477094</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mahal</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>YW</given-names>
              </name>
              <name>
                <surname>Muralidhar</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Mahal</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Choueiri</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Sweeney</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>FY</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Beard</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Trinh</surname>
                <given-names>QD</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>PL</given-names>
              </name>
            </person-group>
            <article-title>Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States.</article-title>
            <source>Ann Oncol</source>
            <year>2017</year>
            <month>May</month>
            <day>01</day>
            <volume>28</volume>
            <issue>5</issue>
            <fpage>1098</fpage>
            <page-range>1098-1104</page-range>
            <pub-id pub-id-type="pmid">28453693</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Omri</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kamil</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Alexander</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Alexander</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Edmond</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ariel</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>David</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gilad</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Azik</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Association between PSA density and pathologically significant prostate cancer: The impact of prostate volume.</article-title>
            <source>Prostate</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>80</volume>
            <issue>16</issue>
            <fpage>1444</fpage>
            <page-range>1444-1449</page-range>
            <pub-id pub-id-type="pmid">32970856</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maggi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Panebianco</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Mosca</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Salciccia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gentilucci</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Di Pierro</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Busetto</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Barchetti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Campa</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sperduti</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Del Giudice</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sciarra</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Prostate Imaging Reporting and Data System 3 Category Cases at Multiparametric Magnetic Resonance for Prostate Cancer: A Systematic Review and Meta-analysis.</article-title>
            <source>Eur Urol Focus</source>
            <year>2020</year>
            <month>May</month>
            <day>15</day>
            <volume>6</volume>
            <issue>3</issue>
            <fpage>463</fpage>
            <page-range>463-478</page-range>
            <pub-id pub-id-type="pmid">31279677</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nordstr&#x000f6;m</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Akre</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Aly</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gr&#x000f6;nberg</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Eklund</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer.</article-title>
            <source>Prostate Cancer Prostatic Dis</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>57</fpage>
            <page-range>57-63</page-range>
            <pub-id pub-id-type="pmid">29259293</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yusim</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Krenawi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mazor</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Novack</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Mabjeesh</surname>
                <given-names>NJ</given-names>
              </name>
            </person-group>
            <article-title>The use of prostate specific antigen density to predict clinically significant prostate cancer.</article-title>
            <source>Sci Rep</source>
            <year>2020</year>
            <month>Nov</month>
            <day>17</day>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>20015</fpage>
            <pub-id pub-id-type="pmid">33203873</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kortenbach</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>L&#x000f8;gager</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Thomsen</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Boesen</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Comparison of PSA density and lesion volume strategies for selecting men with equivocal PI-RADS 3 lesions on bpMRI for biopsies.</article-title>
            <source>Abdom Radiol (NY)</source>
            <year>2023</year>
            <month>Feb</month>
            <volume>48</volume>
            <issue>2</issue>
            <fpage>688</fpage>
            <page-range>688-693</page-range>
            <pub-id pub-id-type="pmid">36318331</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lei</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Gu</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>YK</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>XD</given-names>
              </name>
            </person-group>
            <article-title>Combining prostate-specific antigen density with prostate imaging reporting and data system score version 2.1 to improve detection of clinically significant prostate cancer: A retrospective study.</article-title>
            <source>Front Oncol</source>
            <year>2022</year>
            <volume>12</volume>
            <fpage>992032</fpage>
            <pub-id pub-id-type="pmid">36212411</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Drevik</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dalimov</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Uzzo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Danella</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Guzzo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Belkoff</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Raman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tomaszewski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Trabulsi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Reese</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Singer</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Syed</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Correa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Smaldone</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ginzburg</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Utility of PSA density in patients with PI-RADS 3 lesions across a large multi-institutional collaborative.</article-title>
            <source>Urol Oncol</source>
            <year>2022</year>
            <month>Nov</month>
            <volume>40</volume>
            <issue>11</issue>
            <fpage>490.e1</fpage>
            <page-range>490.e1-490.e6</page-range>
            <pub-id pub-id-type="pmid">36163229</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rodr&#x000ed;guez Cabello</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>M&#x000e9;ndez Rubio</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Platas Sancho</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Carballido Rodr&#x000ed;guez</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic evaluation and incorporation of PSA density and the prostate imaging and data reporting system (PIRADS) version 2 classification in risk-nomograms for prostate cancer.</article-title>
            <source>World J Urol</source>
            <year>2022</year>
            <month>Oct</month>
            <volume>40</volume>
            <issue>10</issue>
            <fpage>2439</fpage>
            <page-range>2439-2450</page-range>
            <pub-id pub-id-type="pmid">35941245</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carter</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Partin</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Luderer</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Metter</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Landis</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Fozard</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Pearson</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis.</article-title>
            <source>Urology</source>
            <year>1997</year>
            <month>Mar</month>
            <volume>49</volume>
            <issue>3</issue>
            <fpage>379</fpage>
            <page-range>379-84</page-range>
            <pub-id pub-id-type="pmid">9123702</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Masieri</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Minervini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vittori</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lanciotti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lanzi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lapini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Carini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Serni</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The role of free to total PSA ratio in prediction of extracapsular tumor extension and biochemical recurrence after radical prostatectomy in patients with PSA between 4 and 10 ng/ml.</article-title>
            <source>Int Urol Nephrol</source>
            <year>2012</year>
            <month>Aug</month>
            <volume>44</volume>
            <issue>4</issue>
            <fpage>1031</fpage>
            <page-range>1031-8</page-range>
            <pub-id pub-id-type="pmid">22315156</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shariat</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Abdel-Aziz</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Roehrborn</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Lotan</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml.</article-title>
            <source>Eur Urol</source>
            <year>2006</year>
            <month>Feb</month>
            <volume>49</volume>
            <issue>2</issue>
            <fpage>293</fpage>
            <page-range>293-302</page-range>
            <pub-id pub-id-type="pmid">16387412</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Catalona</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Beiser</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Serum free prostate specific antigen and prostate specific antigen density measurements for predicting cancer in men with prior negative prostatic biopsies.</article-title>
            <source>J Urol</source>
            <year>1997</year>
            <month>Dec</month>
            <volume>158</volume>
            <issue>6</issue>
            <fpage>2162</fpage>
            <page-range>2162-7</page-range>
            <pub-id pub-id-type="pmid">9366336</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Christensson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bj&#x000f6;rk</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nilsson</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Dahl&#x000e9;n</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Matikainen</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Cockett</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Abrahamsson</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Lilja</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer.</article-title>
            <source>J Urol</source>
            <year>1993</year>
            <month>Jul</month>
            <volume>150</volume>
            <issue>1</issue>
            <fpage>100</fpage>
            <page-range>100-5</page-range>
            <pub-id pub-id-type="pmid">7685416</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leinonen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>L&#x000f6;vgren</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Vornanen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Stenman</surname>
                <given-names>UH</given-names>
              </name>
            </person-group>
            <article-title>Double-label time-resolved immunofluorometric assay of prostate-specific antigen and of its complex with alpha 1-antichymotrypsin.</article-title>
            <source>Clin Chem</source>
            <year>1993</year>
            <month>Oct</month>
            <volume>39</volume>
            <issue>10</issue>
            <fpage>2098</fpage>
            <page-range>2098-103</page-range>
            <pub-id pub-id-type="pmid">7691441</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stenman</surname>
                <given-names>UH</given-names>
              </name>
              <name>
                <surname>Hakama</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Knekt</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Aromaa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Teppo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Leinonen</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer.</article-title>
            <source>Lancet</source>
            <year>1994</year>
            <month>Dec</month>
            <day>10</day>
            <volume>344</volume>
            <issue>8937</issue>
            <fpage>1594</fpage>
            <page-range>1594-8</page-range>
            <pub-id pub-id-type="pmid">7527116</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Partin</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Brawer</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Subong</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>Kelley</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Cox</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Bruzek</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Pannek</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>Prospective evaluation of percent free-PSA and complexed-PSA for early detection of prostate cancer.</article-title>
            <source>Prostate Cancer Prostatic Dis</source>
            <year>1998</year>
            <month>Jun</month>
            <volume>1</volume>
            <issue>4</issue>
            <fpage>197</fpage>
            <page-range>197-203</page-range>
            <pub-id pub-id-type="pmid">12496895</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Catalona</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Partin</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Slawin</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Brawer</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Flanigan</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Richie</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>deKernion</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Scardino</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Lange</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Subong</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>Parson</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Gasior</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Loveland</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Southwick</surname>
                <given-names>PC</given-names>
              </name>
            </person-group>
            <article-title>Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial.</article-title>
            <source>JAMA</source>
            <year>1998</year>
            <month>May</month>
            <day>20</day>
            <volume>279</volume>
            <issue>19</issue>
            <fpage>1542</fpage>
            <page-range>1542-7</page-range>
            <pub-id pub-id-type="pmid">9605898</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>ZZ</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>YJ</given-names>
              </name>
            </person-group>
            <article-title>Value of free/total prostate-specific antigen (f/t PSA) ratios for prostate cancer detection in patients with total serum prostate-specific antigen between 4 and 10&#x0200a;ng/mL: A meta-analysis.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>97</volume>
            <issue>13</issue>
            <fpage>e0249</fpage>
            <pub-id pub-id-type="pmid">29595681</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carroll</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Mohler</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>NCCN Guidelines Updates: Prostate Cancer and Prostate Cancer Early Detection.</article-title>
            <source>J Natl Compr Canc Netw</source>
            <year>2018</year>
            <month>May</month>
            <volume>16</volume>
            <issue>5S</issue>
            <fpage>620</fpage>
            <page-range>620-623</page-range>
            <pub-id pub-id-type="pmid">29784740</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andriole</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Crawford</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Grubb</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Buys</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Chia</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Church</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Fouad</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Gelmann</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Kvale</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Reding</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Weissfeld</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Yokochi</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Clapp</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Rathmell</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Riley</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Hayes</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Kramer</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Izmirlian</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Pinsky</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Prorok</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Gohagan</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Berg</surname>
                <given-names>CD</given-names>
              </name>
              <collab>PLCO Project Team</collab>
            </person-group>
            <article-title>Mortality results from a randomized prostate-cancer screening trial.</article-title>
            <source>N Engl J Med</source>
            <year>2009</year>
            <month>Mar</month>
            <day>26</day>
            <volume>360</volume>
            <issue>13</issue>
            <fpage>1310</fpage>
            <page-range>1310-9</page-range>
            <pub-id pub-id-type="pmid">19297565</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ankerst</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Koniarski</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Leach</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Sanda</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Partin</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Kagan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sokoll</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>IM</given-names>
              </name>
            </person-group>
            <article-title>Updating risk prediction tools: a case study in prostate cancer.</article-title>
            <source>Biom J</source>
            <year>2012</year>
            <month>Jan</month>
            <volume>54</volume>
            <issue>1</issue>
            <fpage>127</fpage>
            <page-range>127-42</page-range>
            <pub-id pub-id-type="pmid">22095849</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schr&#x000f6;der</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Hugosson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Roobol</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Tammela</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Ciatto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nelen</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kwiatkowski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lujan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lilja</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zappa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Denis</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Recker</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Berenguer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>M&#x000e4;&#x000e4;tt&#x000e4;nen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bangma</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Aus</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Villers</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rebillard</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>van der Kwast</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Blijenberg</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Moss</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>de Koning</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Auvinen</surname>
                <given-names>A</given-names>
              </name>
              <collab>ERSPC Investigators</collab>
            </person-group>
            <article-title>Screening and prostate-cancer mortality in a randomized European study.</article-title>
            <source>N Engl J Med</source>
            <year>2009</year>
            <month>Mar</month>
            <day>26</day>
            <volume>360</volume>
            <issue>13</issue>
            <fpage>1320</fpage>
            <page-range>1320-8</page-range>
            <pub-id pub-id-type="pmid">19297566</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Agnello</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Vidali</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Salvaggio</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Agnello</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lo Sasso</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gambino</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Ciaccio</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Prostate Health Index (PHI) as a triage tool for reducing unnecessary magnetic resonance imaging (MRI) in patients at risk of prostate cancer.</article-title>
            <source>Clin Biochem</source>
            <year>2024</year>
            <month>May</month>
            <volume>127-128</volume>
            <fpage>110759</fpage>
            <pub-id pub-id-type="pmid">38583655</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rius Bilbao</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Aguirre Larracoechea</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Valladares Gomez</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Remmers</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mar Medina</surname>
                <given-names>C</given-names>
              </name>
              <collab>Phi Basque Study Group</collab>
            </person-group>
            <article-title>Incorporating PHI in decision making: external validation of the Rotterdam risk calculators for detection of prostate cancer.</article-title>
            <source>World J Urol</source>
            <year>2024</year>
            <month>Mar</month>
            <day>13</day>
            <volume>42</volume>
            <issue>1</issue>
            <fpage>141</fpage>
            <pub-id pub-id-type="pmid">38478041</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tosoian</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Druskin</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Andreas</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mullane</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chappidi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Joo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ghabili</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Agostino</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Macura</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Schaeffer</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Partin</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Sokoll</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>AE</given-names>
              </name>
            </person-group>
            <article-title>Use of the Prostate Health Index for detection of prostate cancer: results from a large academic practice.</article-title>
            <source>Prostate Cancer Prostatic Dis</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>20</volume>
            <issue>2</issue>
            <fpage>228</fpage>
            <page-range>228-233</page-range>
            <pub-id pub-id-type="pmid">28117387</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Potter</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Partin</surname>
                <given-names>AW</given-names>
              </name>
            </person-group>
            <article-title>Tumor markers: an update on human kallikrein 2.</article-title>
            <source>Rev Urol</source>
            <year>2000</year>
            <season>Fall</season>
            <volume>2</volume>
            <issue>4</issue>
            <fpage>221</fpage>
            <page-range>221-2</page-range>
            <pub-id pub-id-type="pmid">16985755</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carroll</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Parsons</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Andriole</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bahnson</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Castle</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Catalona</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Dahl</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Epstein</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Etzioni</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Farrington</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hemstreet</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Kawachi</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lange</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Loughlin</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Lowrance</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Maroni</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mohler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Morgan</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Moses</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Nadler</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Poch</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Scales</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Shaneyfelt</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Smaldone</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Sonn</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sprenkle</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vickers</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Wake</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shead</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Freedman-Cass</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016.</article-title>
            <source>J Natl Compr Canc Netw</source>
            <year>2016</year>
            <month>May</month>
            <volume>14</volume>
            <issue>5</issue>
            <fpage>509</fpage>
            <page-range>509-19</page-range>
            <pub-id pub-id-type="pmid">27160230</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carlsson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Maschino</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schr&#x000f6;der</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bangma</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Steyerberg</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>van der Kwast</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>van Leenders</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vickers</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lilja</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Roobol</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam.</article-title>
            <source>Eur Urol</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>64</volume>
            <issue>5</issue>
            <fpage>693</fpage>
            <page-range>693-9</page-range>
            <pub-id pub-id-type="pmid">23683475</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Voigt</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Zappala</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Vaughan</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Wein</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>The Kallikrein Panel for prostate cancer screening: its economic impact.</article-title>
            <source>Prostate</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>74</volume>
            <issue>3</issue>
            <fpage>250</fpage>
            <page-range>250-9</page-range>
            <pub-id pub-id-type="pmid">24166488</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ravipaty</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Dalvi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tanna</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Andreazi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Friss</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Klotz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Liao</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Garren</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schofield</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Diamandis</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Dobi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Srivastava</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tekumalla</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kiebish</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Vishnudas</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Sarangarajan</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Narain</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Akmaev</surname>
                <given-names>VR</given-names>
              </name>
            </person-group>
            <article-title>Clinical Validation of a Serum Protein Panel (FLNA, FLNB and KRT19) for Diagnosis of Prostate Cancer.</article-title>
            <source>J Mol Biomark Diagn</source>
            <year>2017</year>
            <volume>8</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">29682400</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Truong</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Jarrard</surname>
                <given-names>DF</given-names>
              </name>
            </person-group>
            <article-title>Toward the detection of prostate cancer in urine: a critical analysis.</article-title>
            <source>J Urol</source>
            <year>2013</year>
            <month>Feb</month>
            <volume>189</volume>
            <issue>2</issue>
            <fpage>422</fpage>
            <page-range>422-9</page-range>
            <pub-id pub-id-type="pmid">23017522</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bussemakers</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>van Bokhoven</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Verhaegh</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Smit</surname>
                <given-names>FP</given-names>
              </name>
              <name>
                <surname>Karthaus</surname>
                <given-names>HF</given-names>
              </name>
              <name>
                <surname>Schalken</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Debruyne</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Ru</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Isaacs</surname>
                <given-names>WB</given-names>
              </name>
            </person-group>
            <article-title>DD3: a new prostate-specific gene, highly overexpressed in prostate cancer.</article-title>
            <source>Cancer Res</source>
            <year>1999</year>
            <month>Dec</month>
            <day>01</day>
            <volume>59</volume>
            <issue>23</issue>
            <fpage>5975</fpage>
            <page-range>5975-9</page-range>
            <pub-id pub-id-type="pmid">10606244</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fujita</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nonomura</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Urinary biomarkers of prostate cancer.</article-title>
            <source>Int J Urol</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>25</volume>
            <issue>9</issue>
            <fpage>770</fpage>
            <page-range>770-779</page-range>
            <pub-id pub-id-type="pmid">30129068</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rigau</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Olivan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Garcia</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sequeiros</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Montes</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Col&#x000e1;s</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Llaurad&#x000f3;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Planas</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Torres</surname>
                <given-names>Id</given-names>
              </name>
              <name>
                <surname>Morote</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Revent&#x000f3;s</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Doll</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The present and future of prostate cancer urine biomarkers.</article-title>
            <source>Int J Mol Sci</source>
            <year>2013</year>
            <month>Jun</month>
            <day>17</day>
            <volume>14</volume>
            <issue>6</issue>
            <fpage>12620</fpage>
            <page-range>12620-49</page-range>
            <pub-id pub-id-type="pmid">23774836</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martignano</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Maugeri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gall&#x000e0;</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Conteduca</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>De Giorgi</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Casadio</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Schepisi</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Urinary RNA-based biomarkers for prostate cancer detection.</article-title>
            <source>Clin Chim Acta</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>473</volume>
            <fpage>96</fpage>
            <page-range>96-105</page-range>
            <pub-id pub-id-type="pmid">28807541</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r76">
          <label>76</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hessels</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Klein Gunnewiek</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>van Oort</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Karthaus</surname>
                <given-names>HF</given-names>
              </name>
              <name>
                <surname>van Leenders</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>van Balken</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kiemeney</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Witjes</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Schalken</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer.</article-title>
            <source>Eur Urol</source>
            <year>2003</year>
            <month>Jul</month>
            <volume>44</volume>
            <issue>1</issue>
            <fpage>8</fpage>
            <page-range>8-15; discussion 15-6</page-range>
            <pub-id pub-id-type="pmid">12814669</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r77">
          <label>77</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Gils</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Hessels</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hulsbergen-van de Kaa</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Witjes</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Jansen</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Mulders</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Rittenhouse</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Schalken</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results.</article-title>
            <source>Prostate</source>
            <year>2008</year>
            <month>Aug</month>
            <day>01</day>
            <volume>68</volume>
            <issue>11</issue>
            <fpage>1215</fpage>
            <page-range>1215-22</page-range>
            <pub-id pub-id-type="pmid">18500693</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r78">
          <label>78</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Groskopf</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Aubin</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Deras</surname>
                <given-names>IL</given-names>
              </name>
              <name>
                <surname>Blase</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bodrug</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Brentano</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mathis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pham</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cass</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hodge</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Macairan</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Marks</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Rittenhouse</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer.</article-title>
            <source>Clin Chem</source>
            <year>2006</year>
            <month>Jun</month>
            <volume>52</volume>
            <issue>6</issue>
            <fpage>1089</fpage>
            <page-range>1089-95</page-range>
            <pub-id pub-id-type="pmid">16627561</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r79">
          <label>79</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alshalalfa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Verhaegh</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Gibb</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Santiago-Jim&#x000e9;nez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Erho</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Jordan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yousefi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>LLC</given-names>
              </name>
              <name>
                <surname>Kolisnik</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Chelissery</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Seiler</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Karnes</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Schaeffer</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Lotan</surname>
                <given-names>TT</given-names>
              </name>
              <name>
                <surname>Den</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Freedland</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Davicioni</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Schalken</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patients.</article-title>
            <source>Oncotarget</source>
            <year>2017</year>
            <month>Aug</month>
            <day>01</day>
            <volume>8</volume>
            <issue>31</issue>
            <fpage>50804</fpage>
            <page-range>50804-50813</page-range>
            <pub-id pub-id-type="pmid">28881605</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r80">
          <label>80</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Deras</surname>
                <given-names>IL</given-names>
              </name>
              <name>
                <surname>Aubin</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Blase</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Day</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Koo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Partin</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Ellis</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Marks</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Fradet</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Rittenhouse</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Groskopf</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>PCA3: a molecular urine assay for predicting prostate biopsy outcome.</article-title>
            <source>J Urol</source>
            <year>2008</year>
            <month>Apr</month>
            <volume>179</volume>
            <issue>4</issue>
            <fpage>1587</fpage>
            <page-range>1587-92</page-range>
            <pub-id pub-id-type="pmid">18295257</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r81">
          <label>81</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roobol</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Schr&#x000f6;der</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>van Leeuwen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wolters</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>van den Bergh</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>van Leenders</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Hessels</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test.</article-title>
            <source>Eur Urol</source>
            <year>2010</year>
            <month>Oct</month>
            <volume>58</volume>
            <issue>4</issue>
            <fpage>475</fpage>
            <page-range>475-81</page-range>
            <pub-id pub-id-type="pmid">20637539</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r82">
          <label>82</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haese</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>de la Taille</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>van Poppel</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Marberger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stenzl</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mulders</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Huland</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Abbou</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Remzi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tinzl</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Feyerabend</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stillebroer</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>van Gils</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Schalken</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy.</article-title>
            <source>Eur Urol</source>
            <year>2008</year>
            <month>Nov</month>
            <volume>54</volume>
            <issue>5</issue>
            <fpage>1081</fpage>
            <page-range>1081-8</page-range>
            <pub-id pub-id-type="pmid">18602209</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r83">
          <label>83</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Dobi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Srivastava</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Prostate cancer: diagnostic performance of the PCA3 urine test.</article-title>
            <source>Nat Rev Urol</source>
            <year>2011</year>
            <month>Mar</month>
            <volume>8</volume>
            <issue>3</issue>
            <fpage>123</fpage>
            <page-range>123-4</page-range>
            <pub-id pub-id-type="pmid">21394175</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r84">
          <label>84</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hessels</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Schalken</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Urinary biomarkers for prostate cancer: a review.</article-title>
            <source>Asian J Androl</source>
            <year>2013</year>
            <month>May</month>
            <volume>15</volume>
            <issue>3</issue>
            <fpage>333</fpage>
            <page-range>333-9</page-range>
            <pub-id pub-id-type="pmid">23524531</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r85">
          <label>85</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Qu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lian</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic significance of urinary long non-coding PCA3 RNA in prostate cancer.</article-title>
            <source>Oncotarget</source>
            <year>2017</year>
            <month>Aug</month>
            <day>29</day>
            <volume>8</volume>
            <issue>35</issue>
            <fpage>58577</fpage>
            <page-range>58577-58586</page-range>
            <pub-id pub-id-type="pmid">28938580</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r86">
          <label>86</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ankerst</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Hoefler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bock</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Goodman</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Vickers</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hernandez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sokoll</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Sanda</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Leach</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>IM</given-names>
              </name>
            </person-group>
            <article-title>Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer.</article-title>
            <source>Urology</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>83</volume>
            <issue>6</issue>
            <fpage>1362</fpage>
            <page-range>1362-7</page-range>
            <pub-id pub-id-type="pmid">24862395</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r87">
          <label>87</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sreenath</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Dobi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Petrovics</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Srivastava</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Oncogenic activation of ERG: A predominant mechanism in prostate cancer.</article-title>
            <source>J Carcinog</source>
            <year>2011</year>
            <volume>10</volume>
            <fpage>37</fpage>
            <pub-id pub-id-type="pmid">22279422</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r88">
          <label>88</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tomlins</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Rhodes</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Perner</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dhanasekaran</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Mehra</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>XW</given-names>
              </name>
              <name>
                <surname>Varambally</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Tchinda</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kuefer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Montie</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Pienta</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Chinnaiyan</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.</article-title>
            <source>Science</source>
            <year>2005</year>
            <month>Oct</month>
            <day>28</day>
            <volume>310</volume>
            <issue>5748</issue>
            <fpage>644</fpage>
            <page-range>644-8</page-range>
            <pub-id pub-id-type="pmid">16254181</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r89">
          <label>89</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rice</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Whitman</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Blase</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ibrahim</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Elsamanoudi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Brassell</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Furusato</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Stingle</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sesterhenn</surname>
                <given-names>IA</given-names>
              </name>
              <name>
                <surname>Petrovics</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Miick</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rittenhouse</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Groskopf</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>McLeod</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Srivastava</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of the ETS-related gene mRNA in urine for the detection of prostate cancer.</article-title>
            <source>Clin Cancer Res</source>
            <year>2010</year>
            <month>Mar</month>
            <day>01</day>
            <volume>16</volume>
            <issue>5</issue>
            <fpage>1572</fpage>
            <page-range>1572-6</page-range>
            <pub-id pub-id-type="pmid">20160063</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r90">
          <label>90</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tomlins</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Aubin</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Siddiqui</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lonigro</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Sefton-Miller</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Miick</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Williamsen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hodge</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Meinke</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Blase</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Penabella</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Day</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Varambally</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sanda</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Rhodes</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Hollenbeck</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sakamoto</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Silberstein</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Fradet</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Amberson</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Meyers</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Palanisamy</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rittenhouse</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Groskopf</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chinnaiyan</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA.</article-title>
            <source>Sci Transl Med</source>
            <year>2011</year>
            <month>Aug</month>
            <day>03</day>
            <volume>3</volume>
            <issue>94</issue>
            <fpage>94ra72</fpage>
            <pub-id pub-id-type="pmid">21813756</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r91">
          <label>91</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Van Neste</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hendriks</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Dijkstra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Trooskens</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cornel</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Jannink</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>de Jong</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hessels</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Smit</surname>
                <given-names>FP</given-names>
              </name>
              <name>
                <surname>Melchers</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Leyten</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>de Reijke</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Vergunst</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kil</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Knipscheer</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Hulsbergen-van de Kaa</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Mulders</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>van Oort</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Van Criekinge</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Schalken</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score.</article-title>
            <source>Eur Urol</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>70</volume>
            <issue>5</issue>
            <fpage>740</fpage>
            <page-range>740-748</page-range>
            <pub-id pub-id-type="pmid">27108162</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r92">
          <label>92</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schostak</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schwall</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Poznanovi&#x00107;</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Groebe</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Messinger</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Krause</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Pelzer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Horninger</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Klocker</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hennenlotter</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Feyerabend</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stenzl</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schrattenholz</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Annexin A3 in urine: a highly specific noninvasive marker for prostate cancer early detection.</article-title>
            <source>J Urol</source>
            <year>2009</year>
            <month>Jan</month>
            <volume>181</volume>
            <issue>1</issue>
            <fpage>343</fpage>
            <page-range>343-53</page-range>
            <pub-id pub-id-type="pmid">19012935</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r93">
          <label>93</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cao</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>YX</given-names>
              </name>
              <name>
                <surname>Yao</surname>
                <given-names>XD</given-names>
              </name>
            </person-group>
            <article-title>A multiplex model of combining gene-based, protein-based, and metabolite-based with positive and negative markers in urine for the early diagnosis of prostate cancer.</article-title>
            <source>Prostate</source>
            <year>2011</year>
            <month>May</month>
            <day>15</day>
            <volume>71</volume>
            <issue>7</issue>
            <fpage>700</fpage>
            <page-range>700-10</page-range>
            <pub-id pub-id-type="pmid">20957673</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r94">
          <label>94</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Duijvesz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Luider</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bangma</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Jenster</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Exosomes as biomarker treasure chests for prostate cancer.</article-title>
            <source>Eur Urol</source>
            <year>2011</year>
            <month>May</month>
            <volume>59</volume>
            <issue>5</issue>
            <fpage>823</fpage>
            <page-range>823-31</page-range>
            <pub-id pub-id-type="pmid">21196075</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r95">
          <label>95</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Filella</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Foj</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers.</article-title>
            <source>Int J Mol Sci</source>
            <year>2016</year>
            <month>Oct</month>
            <day>26</day>
            <volume>17</volume>
            <issue>11</issue>
            <pub-id pub-id-type="pmid">27792187</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r96">
          <label>96</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McKiernan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Donovan</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>O'Neill</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bentink</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Noerholm</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Belzer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Skog</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kattan</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Partin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Andriole</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Carroll</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy.</article-title>
            <source>JAMA Oncol</source>
            <year>2016</year>
            <month>Jul</month>
            <day>01</day>
            <volume>2</volume>
            <issue>7</issue>
            <fpage>882</fpage>
            <page-range>882-9</page-range>
            <pub-id pub-id-type="pmid">27032035</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r97">
          <label>97</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Donovan</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Noerholm</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bentink</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Belzer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Skog</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>O'Neill</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Cochran</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>GA</given-names>
              </name>
            </person-group>
            <article-title>A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result.</article-title>
            <source>Prostate Cancer Prostatic Dis</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>18</volume>
            <issue>4</issue>
            <fpage>370</fpage>
            <page-range>370-5</page-range>
            <pub-id pub-id-type="pmid">26345389</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r98">
          <label>98</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Intasqui</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bertolla</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Sadi</surname>
                <given-names>MV</given-names>
              </name>
            </person-group>
            <article-title>Prostate cancer proteomics: clinically useful protein biomarkers and future perspectives.</article-title>
            <source>Expert Rev Proteomics</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>65</fpage>
            <page-range>65-79</page-range>
            <pub-id pub-id-type="pmid">29251021</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r99">
          <label>99</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Worst</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>von Hardenberg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gross</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Erben</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Schn&#x000f6;lzer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hausser</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Bugert</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Michel</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Boutros</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Database-augmented Mass Spectrometry Analysis of Exosomes Identifies Claudin 3 as a Putative Prostate Cancer Biomarker.</article-title>
            <source>Mol Cell Proteomics</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>16</volume>
            <issue>6</issue>
            <fpage>998</fpage>
            <page-range>998-1008</page-range>
            <pub-id pub-id-type="pmid">28396511</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r100">
          <label>100</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jutzy</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Valenzuela</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Turay</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Aspe</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Ashok</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mirshahidi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mercola</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lilly</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Wall</surname>
                <given-names>NR</given-names>
              </name>
            </person-group>
            <article-title>Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer.</article-title>
            <source>PLoS One</source>
            <year>2012</year>
            <volume>7</volume>
            <issue>10</issue>
            <fpage>e46737</fpage>
            <pub-id pub-id-type="pmid">23091600</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r101">
          <label>101</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sartori</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>Biomarkers in prostate cancer: what's new?</article-title>
            <source>Curr Opin Oncol</source>
            <year>2014</year>
            <month>May</month>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>259</fpage>
            <page-range>259-64</page-range>
            <pub-id pub-id-type="pmid">24626128</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r102">
          <label>102</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eifler</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Partin</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Humphreys</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Epstein</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Trock</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Partin</surname>
                <given-names>AW</given-names>
              </name>
            </person-group>
            <article-title>An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011.</article-title>
            <source>BJU Int</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>111</volume>
            <issue>1</issue>
            <fpage>22</fpage>
            <page-range>22-9</page-range>
            <pub-id pub-id-type="pmid">22834909</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r103">
          <label>103</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fujita</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pavlovich</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Netto</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Konishi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Isaacs</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>De Marzo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Meeker</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>Specific detection of prostate cancer cells in urine by multiplex immunofluorescence cytology.</article-title>
            <source>Hum Pathol</source>
            <year>2009</year>
            <month>Jul</month>
            <volume>40</volume>
            <issue>7</issue>
            <fpage>924</fpage>
            <page-range>924-33</page-range>
            <pub-id pub-id-type="pmid">19368959</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r104">
          <label>104</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nickens</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Scoggin</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Ravindranath</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>McLeod</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Dobi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tacha</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sesterhenn</surname>
                <given-names>IA</given-names>
              </name>
              <name>
                <surname>Srivastava</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Petrovics</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Prostate cancer marker panel with single cell sensitivity in urine.</article-title>
            <source>Prostate</source>
            <year>2015</year>
            <month>Jun</month>
            <day>15</day>
            <volume>75</volume>
            <issue>9</issue>
            <fpage>969</fpage>
            <page-range>969-75</page-range>
            <pub-id pub-id-type="pmid">25808739</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r105">
          <label>105</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsampoukas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Manolas</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dellis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Deliveliotis</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Moussa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Papatsoris</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Atypical small acinar proliferation and its significance in pathological reports in modern urological times.</article-title>
            <source>Asian J Urol</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>12</fpage>
            <page-range>12-17</page-range>
            <pub-id pub-id-type="pmid">35198392</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r106">
          <label>106</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Adamczyk</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wolski</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Butkiewicz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nussbeutel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Drewa</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Significance of atypical small acinar proliferation and extensive high-grade prostatic intraepithelial neoplasm in clinical practice.</article-title>
            <source>Cent European J Urol</source>
            <year>2014</year>
            <volume>67</volume>
            <issue>2</issue>
            <fpage>136</fpage>
            <page-range>136-41</page-range>
            <pub-id pub-id-type="pmid">25140226</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r107">
          <label>107</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bostwick</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Brawer</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Qian</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>High-grade prostatic intraepithelial neoplasia.</article-title>
            <source>Rev Urol</source>
            <year>2004</year>
            <season>Fall</season>
            <volume>6</volume>
            <issue>4</issue>
            <fpage>171</fpage>
            <page-range>171-9</page-range>
            <pub-id pub-id-type="pmid">16985598</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r108">
          <label>108</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhou</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>High-grade prostatic intraepithelial neoplasia, PIN-like carcinoma, ductal carcinoma, and intraductal carcinoma of the prostate.</article-title>
            <source>Mod Pathol</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>31</volume>
            <issue>S1</issue>
            <fpage>S71</fpage>
            <page-range>S71-79</page-range>
            <pub-id pub-id-type="pmid">29297491</pub-id>
          </element-citation>
        </ref>
        <ref id="article-144254.r109">
          <label>109</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morote</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schwartzmann</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Celma</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Roche</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>de Torres</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Mast</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Semidey</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Regis</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Santamaria</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Planas</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Trilla</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>The current recommendation for the management of isolated high-grade prostatic intraepithelial neoplasia.</article-title>
            <source>BJU Int</source>
            <year>2022</year>
            <month>May</month>
            <volume>129</volume>
            <issue>5</issue>
            <fpage>627</fpage>
            <page-range>627-633</page-range>
            <pub-id pub-id-type="pmid">34375498</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
